10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934.

For the quarterly period ended June 30, 2010.

OR

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from              to             .

Commission File Number 0-27570

PHARMACEUTICAL PRODUCT

DEVELOPMENT, INC.

(Exact name of registrant as specified in its charter)

North Carolina	56-1640186
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)

929 North Front Street

Wilmington, North Carolina

(Address of principal executive offices)

28401

(Zip Code)

Registrant’s telephone number, including area code: (910) 251-0081

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its Corporate website every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x	Accelerated filer	¨
Non-accelerated filer	¨  (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 118,816,560 shares of common stock, par value $0.05 per share, as of July 28, 2010.

INDEX

	Page
Part I. FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Condensed Statements of Income for the Three and Six Months Ended June 30, 2009 and 2010 (unaudited)	3
Consolidated Condensed Balance Sheets as of December 31, 2009 and June 30, 2010 (unaudited)	4
Consolidated Condensed Statements of Cash Flows for the Six Months Ended June 30, 2009 and 2010 (unaudited)	5
Notes to Consolidated Condensed Financial Statements (unaudited)	6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3. Quantitative and Qualitative Disclosures about Market Risk	35
Item 4. Controls and Procedures	36
Part II. OTHER INFORMATION
Item 6. Exhibits	36
Signatures	37

2

Part I. FINANCIAL INFORMATION

Item 1. Financial Statements

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

CONSOLIDATED CONDENSED STATEMENTS OF INCOME

(in thousands, except per share data)

(unaudited)

	Three Months Ended June  30,					Six Months Ended June 30,
	2009		2010			2009		2010
Net revenue:
Development	$	330,179	$	333,779		$	665,533	$	657,606
Discovery Sciences		162		7,717			5,324		8,010
Reimbursed out-of-pockets		24,257		28,423			48,111		51,072
Total net revenue		354,598		369,919			718,968		716,688
Direct costs:
Development		158,486		163,773			322,655		323,774
Discovery Sciences		145		(26	)		440		126
Reimbursable out-of-pocket expenses		24,257		28,423			48,111		51,072
Total direct costs		182,888		192,170			371,206		374,972
Research and development expenses		979		8,445			2,290		14,783
Selling, general and administrative expenses		96,648		112,106			189,783		225,016
Depreciation and amortization		15,819		17,114			30,837		34,151
Total operating expenses		296,334		329,835			594,116		648,922
Operating income		58,264		40,084			124,852		67,766
Loss from equity method investment		—		(1,747	)		—		(3,789	)
Other income, net		1,075		2,747			857		4,020
Income from continuing operations before provision for income taxes		59,339		41,084			125,709		67,997
Provision for income taxes		17,894		17,522			39,124		26,153
Income from continuing operations		41,445		23,562			86,585		41,844
Income (loss) from discontinued operations, net of provision for income taxes		16,616		(2,585	)		16,045		(3,662	)
Net income	$	58,061	$	20,977		$	102,630	$	38,182
Basic and diluted income per common share from continuing operations	$	0.35	$	0.20		$	0.73	$	0.35
Basic and diluted income (loss) per common share from discontinued operations	$	0.14	$	(0.02	)	$	0.14	$	(0.03	)
Basic and diluted net income per common share	$	0.49	$	0.18		$	0.87	$	0.32
Dividends declared per common share	$	0.15	$	0.15		$	0.275	$	0.30
Weighted-average number of common shares outstanding:
Basic		117,893		118,542			117,860		118,501
Dilutive effect of stock options and restricted stock		446		373			584		277
Diluted		118,339		118,915			118,444		118,778

The accompanying notes are an integral part of these consolidated condensed financial statements.

3

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

CONSOLIDATED CONDENSED BALANCE SHEETS

(in thousands)

(unaudited)

Assets
	December 31, 2009			June 30, 2010
Current assets:
Cash and cash equivalents	$	408,903		$	434,074
Short-term investments		144,645			58,056
Accounts receivable and unbilled services, net		429,670			399,073
Income tax receivable		16,887			15,526
Investigator advances		13,980			17,580
Prepaid expenses		24,458			26,533
Deferred tax assets		26,068			26,733
Cash held in escrow		12,415			16,889
Other current assets		55,115			31,358
Total current assets		1,132,141			1,025,822
Property and equipment, net		388,459			373,279
Goodwill		323,383			268,875
Long-term investments		88,558			83,010
Other investments		44,641			47,132
Intangible assets		24,315			22,387
Deferred tax assets		11,959			11,463
Other assets		16,747			13,739
Total assets	$	2,030,203		$	1,845,707
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable	$	34,005		$	30,530
Payables to investigators		54,428			52,099
Accrued income taxes		4,043			5,748
Other accrued expenses		200,720			196,563
Unearned income		297,844			300,532
Total current liabilities		591,040			585,472
Accrued income taxes		34,268			35,469
Accrued additional pension liability		15,434			15,068
Deferred rent		14,334			17,028
Other long-term liabilities		29,000			11,191
Total liabilities		684,076			664,228
Shareholders’ equity:
Common stock		5,913			5,929
Paid-in capital		576,069			591,250
Retained earnings		776,110			632,029
Accumulated other comprehensive loss		(11,965	)		(47,729	)
Total shareholders’ equity		1,346,127			1,181,479
Total liabilities and shareholders’ equity	$	2,030,203		$	1,845,707

The accompanying notes are an integral part of these consolidated condensed financial statements.

4

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	Six Months Ended June  30,
	2009			2010
Cash flows from operating activities:
Net income	$	102,630		$	38,182
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		31,492			35,164
Stock compensation expense		9,749			9,649
Gain on sale of business, net of taxes		(19,452	)		—
Loss from equity investment, net of taxes		—			2,469
Provision (benefit) for deferred income taxes		3,775			(3,231	)
Other		(544	)		1,531
Change in operating assets and liabilities		(45,723	)		37,725
Net cash provided by operating activities		81,927			121,489
Cash flows from investing activities:
Purchases of property and equipment		(23,484	)		(27,156	)
Proceeds from sale of property and equipment		249			57
Proceeds from sale of business		42,095			3,464
Purchases of investments		—			(3,179	)
Maturities and sales of investments		16,980			98,039
Proceeds from sale of equity investments		716			—
Net cash paid for acquisitions		(35,015	)		(10,169	)
Changes in restricted cash		—			3,000
Purchase of intangibles		(500	)		—
Loan advances		—			(4,000	)
Purchases of other investments		(1,980	)		(7,030	)
Net cash (used in) provided by investing activities		(939	)		53,026
Cash flows from financing activities:
Proceeds from exercise of stock options and employee stock purchase plan		6,042			6,143
Income tax benefit from exercise of stock options and disqualifying dispositions of stock		136			138
Cash and cash equivalents contributed to Furiex
Pharmaceuticals, Inc.		—			(100,000	)
Cash dividends paid		(32,434	)		(35,581	)
Net cash used in financing activities		(26,256	)		(129,300	)
Effect of exchange rate changes on cash and cash equivalents		13,353			(20,044	)
Net increase in cash and cash equivalents		68,085			25,171
Cash and cash equivalents, beginning of the period		491,755			408,903
Cash and cash equivalents, end of the period	$	559,840		$	434,074

The accompanying notes are an integral part of these consolidated condensed financial statements.

5

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(numbers in tables in thousands)

(unaudited)

1. Significant Accounting Policies

The significant accounting policies followed by Pharmaceutical Product Development, Inc. and its subsidiaries (collectively, the “Company”) for interim financial reporting are consistent with the accounting policies followed for annual financial reporting. The Company prepared these unaudited consolidated condensed financial statements in accordance with Rule 10-01 of Regulation S-X and, in management’s opinion, has included all adjustments of a normal recurring nature necessary for a fair presentation. The accompanying consolidated condensed financial statements should be read in conjunction with the consolidated financial statements and notes thereto in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009. The results of operations for the three-month and six-month periods ended June 30, 2010 are not necessarily indicative of the results to be expected for the full year or any other period. The amounts in the December 31, 2009 consolidated condensed balance sheet are derived from the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009.

On June 14, 2010, the Company spun off its compound partnering business. Substantially all of the operating business components of the Discovery Sciences segment were included in the spin-off. The Company contributed $100.0 million of cash and cash equivalents to Furiex Pharmaceuticals, Inc. and all outstanding shares of Furiex were then distributed to the Company’s shareholders as a pro-rata, tax-free dividend on June 14, 2010 by issuing one share of Furiex common stock for every twelve shares of the Company’s common stock to shareholders of record on June 1, 2010. The separation resulted in Furiex operating as an independent entity with its own publicly-traded stock. The results of operations for the former compound partnering business conducted by the Company until June 14, 2010 are included as part of this report as continuing operations. The Company does not have any equity or other form of ownership interest in Furiex subsequent to the separation. For further details, see Note 14.

Principles of Consolidation

The accompanying unaudited consolidated condensed financial statements include the accounts and results of operations of the Company. All intercompany balances and transactions have been eliminated in consolidation.

Recent Accounting Pronouncements

In June 2009, the Financial Accounting Standards Board, or FASB, issued a new accounting standard modifying how a company determines when an entity that is insufficiently capitalized or is not controlled through voting (or similar rights) should be consolidated. This standard clarifies that the determination of whether a company is required to consolidate an entity is based on, among other things, an entity’s purpose and design and a company’s ability to direct the activities of the entity that most significantly impact the entity’s economic performance. This standard requires an ongoing reassessment of whether a company is the primary beneficiary of a variable interest entity and requires additional disclosures about a company’s involvement in variable interest entities and any significant changes in risk exposure due to that involvement. This standard was effective on January 1, 2010. The adoption of this standard had no impact on the Company’s financial statements.

In March 2010, the Emerging Issues Task Force of the FASB issued a new accounting standard, the objective of which is to establish a revenue recognition model for contingent consideration that is payable upon the achievement of an uncertain future event, referred to as a milestone. This consensus will apply to milestones in single or multiple-deliverable arrangements involving research and development transactions, and will be effective for fiscal years (and interim periods within those fiscal years) beginning on or after June 15, 2010. The Company does not expect the adoption of this standard to have a material impact on its financial statements.

6

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(numbers in tables in thousands)

(unaudited)

1. Significant Accounting Policies

Earnings per Share

The Company computes basic income per share information based on the weighted-average number of common shares outstanding during the period. The Company computes diluted income per share information based on the weighted-average number of common shares outstanding during the period plus the effects of any dilutive common stock equivalents. The Company excluded 6,129,295 shares and 5,288,542 shares from the calculation of diluted earnings per share during the three months ended June 30, 2009 and 2010, respectively, and 6,078,772 shares and 6,697,784 shares from the calculation of diluted earnings per share during the six months ended June 30, 2009 and 2010, respectively, because they were antidilutive. The antidilutive shares consist of shares underlying stock options, employee stock purchase plan subscriptions and restricted stock that were antidilutive for the period.

Use of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

2. Acquisitions and Dispositions

In April 2009, the Company acquired 100 percent of the outstanding equity interests of AbC.R.O., Inc., a contract research organization operating in Central and Eastern Europe, for total consideration of $40.0 million. Of this amount, the Company paid $36.4 million at closing and deposited the remaining $3.6 million into an escrow account to secure indemnification claims. The escrowed funds are scheduled to be released in the second quarter of 2011. The escrowed funds are recorded as a component of other accrued expenses as of June 30, 2010. Through the acquisition, the Company expanded its infrastructure in this region for clinical research by adding offices in Romania, Bulgaria, Serbia and Croatia, and strengthened its operations in other countries in the region. This acquisition is included in the Company’s Development segment. The fair value of the financial assets acquired included accounts receivable of $3.9 million and unbilled receivables of $2.4 million.

In April 2009, the Company acquired 100 percent of the outstanding equity interests of Magen BioSciences, Inc., a biotechnology company focused on the development of dermatologic therapies, for total consideration of $14.9 million. Of this amount, the Company paid $13.1 million at closing and deposited the remaining $1.8 million into an escrow account to secure indemnification claims. In the second quarter of 2010, we made a claim against the former Magen stockholders under the merger agreement, and therefore have not released the escrowed funds, pending resolution of our claim. The escrowed funds were recorded as a component of other accrued expenses as of June 30, 2010. Through the acquisition, the Company expanded its former compound partnering program to include dermatological drug discovery and gained screening capability for dermatologic compounds. This acquisition is included in the Company’s Discovery Sciences segment. As discussed below, in May 2010, the Company discontinued the operations of this business unit.

7

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(numbers in tables in thousands)

(unaudited)

2. Acquisitions and Dispositions

In November 2009, the Company acquired 100 percent of the outstanding equity interests of Excel PharmaStudies, Inc., a contract research organization operating in China. The total purchase price was $22.2 million, subject to final working capital adjustments. Of this amount, the Company paid $15.7 million at closing and an additional $2.0 million in the second quarter of 2010. At closing, the Company also deposited $4.5 million of the purchase price into an escrow account to secure indemnification claims, which is scheduled to be released by May 2011. The escrowed funds were recorded as a component of other accrued expenses as of June 30, 2010. Through the acquisition, the Company expanded its operations in China and believes it should improve its ability to offer its services in the Asia Pacific region. This acquisition is included in the Company’s Development segment. The fair value of the financial assets acquired included accounts receivable of $1.6 million.

In November 2009, the Company acquired 100 percent of the outstanding equity interests of BioDuro LLC, a drug discovery services company focused on integrated drug discovery programs and services in China, for total consideration of $78.6 million. As of June 30, 2010, the Company had paid $69.6 million. The Company deposited the remaining $9.0 million of the purchase price into an escrow account to secure indemnification claims and the payment of other obligations. The escrowed funds are scheduled to be released by November 2012. Of the $9.0 million escrowed funds, $6.9 million was recorded as a component of other accrued expenses and $2.1 million was recorded as a component of other long-term liabilities as of June 30, 2010. Through the acquisition, the Company expanded its drug development capabilities within the region. This acquisition is included in the Company’s Development segment. The fair value of the financial assets acquired included accounts receivables, net of $3.2 million and unbilled receivables of $1.6 million.

Acquisition costs related to AbC.R.O., Magen, Excel and BioDuro were not significant and were included in selling, general and administrative costs in the consolidated condensed statements of income.

As of June 30, 2010, the Company held $18.9 million in escrow relating to payments to be made for the AbC.R.O., Magen, Excel and BioDuro acquisitions, of which $16.9 million is reflected as cash held in escrow in the accompanying consolidated condensed balance sheet and $2.0 million is reflected as a component of other assets. These escrows secure the indemnification provisions of the purchase agreements and the payment of other obligations. These balances are classified as current or long-term based on the expected date of the release of the funds to the sellers.

The Company accounted for these acquisitions under the purchase method of accounting. Accordingly, the Company allocated the total purchase price for these acquisitions to the estimated fair value of assets acquired and liabilities assumed, which are set forth in the following table:

	AbC.R.O.			Magen			Excel			BioDuro
Value of net assets:
Current assets	$	9,935		$	3,625		$	4,145		$	7,114
Property and equipment, net		1,025			609			594			5,850
Other assets		90			—			—			415
Current liabilities		(4,780	)		(1,246	)		(3,265	)		(5,855	)
Other long-term liabilities		—			—			—			(1,668	)
Value of identifiable intangible assets:
Backlog and customer relationships		7,920			—			3,049			9,810
In-process research and development		—			10,361			—			—
Goodwill		25,843			1,517			17,722			62,897
Total	$	40,033		$	14,866		$	22,245		$	78,563

Pro forma results of operations prior to the dates of acquisition have not been presented because the pro forma results are not materially different from the actual results presented.

8

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(numbers in tables in thousands)

(unaudited)

2. Acquisitions and Dispositions

The Company will not be able to deduct the goodwill related to the AbC.R.O., Magen, Excel or BioDuro acquisitions for tax purposes.

Dispositions

In May 2009, the Company completed the disposition of substantially all of the assets of its wholly owned subsidiary Piedmont Research Center, LLC for total consideration of $46.0 million. As of December 31, 2009, the purchaser had an indemnification holdback of $3.4 million, which was included as a component of other current assets. The Company received the $3.4 million in the first quarter of 2010. Piedmont Research Center provided preclinical research services and was included in the Company’s Discovery Sciences segment.

In December 2009, the Company completed the disposition of its wholly owned subsidiary PPD Biomarker Discovery Sciences, LLC for total consideration of $0.1 million and the right to receive a percentage of the revenue received by the purchaser on contracts awarded as of the date of the acquisition. Contingent consideration will be recognized when and if received in the future. PPD Biomarker Discovery Sciences provided biomarker discovery services and participant sample analysis.

Due to the unique service offerings of these subsidiaries, the Company determined these business units were no longer a long-term strategic fit and elected to sell them.

In May 2010, the Company discontinued the operations of its wholly owned subsidiary PPD Dermatology, Inc. due to unfavorable efficacy data associated with the MAG-131 program.

The results of Piedmont Research Center, PPD Biomarker Discovery Sciences and PPD Dermatology are reported as discontinued operations within the consolidated condensed statements of income as set forth in the following table:

	Three Months Ended June  30,						Six Months Ended June 30,
	2009			2010			2009			2010
Net revenue	$	1,699		$	—		$	5,797		$	—
Loss from discontinued operations		(4,929	)		(2,833	)		(5,757	)		(4,444	)
Gain on sale of business		35,505			—			35,505			—
Provision (benefit) for income taxes		13,960			(248	)		13,703			782
Income (loss) from discontinued operations, net of provision for income taxes		16,616			(2,585	)		16,045			(3,662	)

9

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(numbers in tables in thousands)

(unaudited)

3. Cash and Cash Equivalents, Short-term Investments, Long-term Investments and Other Investments

Cash and cash equivalents, short-term investments, long-term investments and other investments were composed of the following as of the dates set forth below:

	Cash and
	Cash		Short-term		Long-term		Other		Unrealized		Unrealized
	Equivalents		Investments		Investments		Investments		Gains		Losses
As of December 31, 2009
Cash	$	228,482
Money market funds		180,421
Auction rate securities					$	88,558					$	21,317
Municipal debt securities			$	36,000					$	153		36
Corporate debt securities – FDIC insured				12,713						48		3
Treasury securities				95,932						36		7
Equity method investment:
Celtic Therapeutics Holdings, L.P.							$	31,426
Cost basis investments:
Bay City Capital Funds								9,181
A.M. Pappas Funds								3,593
Other investments								441
Total	$	408,903	$	144,645	$	88,558	$	44,641	$	237	$	21,363
As of June 30, 2010
Cash	$	208,564
Money market funds		225,510
Auction rate securities			$	6,800	$	83,010					$	18,165
Municipal debt securities				29,265					$	189
Corporate debt securities – FDIC insured				12,733						123
Treasury securities				9,258						121
Equity method investment:
Celtic Therapeutics Holdings, L.P.							$	27,637
Cost basis investments:
Bay City Capital Funds								9,708
A.M. Pappas Funds								3,653
Other investments								6,134
Total	$	434,074	$	58,056	$	83,010	$	47,132	$	433	$	18,165

10

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(numbers in tables in thousands)

(unaudited)

3. Cash and Cash Equivalents, Short-term Investments, Long-term Investments and Other Investments

Short-term and Long-term Investments

The Company classifies its short-term and long-term investments as available-for-sale securities. The Company determines realized and unrealized gains and losses on short-term and long-term investments on a specific identification basis.

For the three months and six months ended June 30, 2009 and 2010, the Company had the following gross realized gains and losses on investments:

	Three Months Ended June  30,				Six Months Ended June  30,
	2009		2010		2009		2010
Gross realized gains on other investments	$	716	$	3,340	$	716	$	3,340
Gross realized gains on municipal debt securities		—		—		—		4
Gross realized loss on other investments		—		750		—		750
Gross realized losses on municipal debt securities		—		—		—		53

The Company held $88.6 million and $89.8 million, net of unrealized loss, in auction rate securities at December 31, 2009 and June 30, 2010, respectively. The Company’s portfolio of investments in auction rate securities consists principally of interests in government-guaranteed student loans, insured municipal debt obligations and municipal preferred auction rate securities. Except for $6.8 million of securities sold in July 2010, the entire balance of auction rate securities were classified as long-term investments as of June 30, 2010 due to continuing uncertainties about the liquidity of the auction rate securities market. The Company also recorded an unrealized loss on these investments of $21.3 million and $18.2 million as of December 31, 2009 and June 30, 2010, respectively. The Company recorded this unrealized loss based on a Level 3 valuation, including assumptions about appropriate maturity periods of the instruments by utilizing a 3 to 5 year workout period based on industry expectations, market interest rates for comparable securities, and the credit-worthiness of the underlying issuers. The Company concluded that this impairment was temporary because of its ability and intent to hold the auction rate securities until the fair value recovers. The Company will continue to seek to liquidate these investments at par value and will review the classification and valuation of these securities on a quarterly basis.

11

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(numbers in tables in thousands)

(unaudited)

3. Cash and Cash Equivalents, Short-term Investments, Long-term Investments and Other Investments

Equity Method Investment

In October 2009, the Company committed to invest up to $102.7 million in Celtic Therapeutics Holdings, L.P., or Celtic. Celtic is an investment partnership organized for the purpose of identifying, acquiring and investing in a diversified portfolio of novel therapeutic product candidates, with a focus on mid-stage compounds that have progressed through human proof of concept studies and that are targeted to address unmet medical needs. As of June 30, 2010, the Company had invested a total of $32.7 million of the aggregate commitment. For the three months and six months ended June 30, 2010, the Company recognized a loss of $1.7 million and $3.8 million, respectively, which is based on the Company’s percentage ownership of Celtic’s losses. As of June 30, 2010, the Company had an investment balance of $27.6 million, which includes cumulative investment losses to date. The Company expects to invest the remainder of its commitment over a period of four years.

Other Investments

The Company is a limited partner in several venture capital funds established for the purpose of investing in life sciences and healthcare companies. These funds require the Company to commit to make investments in the funds over a period of time. Although the funding commitment to A.M. Pappas Life Science Ventures, III, L.P. has expired for new investments, the Company is still required to fund additional investments in existing fund investments and the ongoing operation of the fund. The Company accounts for these funds as cost basis investments and determines realized and unrealized losses on a specific identification method.

The Company is a stockholder in Accelerator III Corporation and certain of its incubator companies. Accelerator III requires the Company to make investments upon request up to its committed capital amount. The Company accounts for this investment as a cost basis investment and determines realized and unrealized losses on a specific identification method.

The Company’s capital commitments in these funds at June 30, 2010 were as follows:

Fund	Ownership		Total Capital Commitment		Remaining Commitment		Commitment Expiration
Bay City Capital Fund IV, L.P.	2.9	%	$	10,000	$	2,142	September 2010
Bay City Capital Fund V, L.P.	2.0	%		10,000		7,151	October 2012
A.M. Pappas Life Science Ventures III, L.P.	4.7	%		4,750		1,045	December 2009
A.M. Pappas Life Science Ventures IV, L.P.	3.0	%		2,935		2,436	February 2014
Accelerator III and incubator companies (1)	19.9	%		4,602		2,142	None

⁽¹⁾ The Company’s percentage ownership of incubator companies might vary but will not exceed 19.9%.

In May 2010, the Company invested $5.0 million for a 12.2% ownership interest in Liquidia Technologies, Inc. The Company accounts for this investment as a cost basis investment and determines realized and unrealized losses on a specific identification method.

In the second quarter of 2010, the Company recorded a $3.3 million pretax gain on the sale of a cost basis investment that had previously been fully impaired. The investment was sold in connection with the acquisition of the investee by a major pharmaceutical company. The proceeds of the sale are anticipated to be received in July 2010 and the receivable has been recorded as a component of other current assets.

12

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(numbers in tables in thousands)

(unaudited)

4. Accounts Receivable and Unbilled Services

Accounts receivable and unbilled services, net, consisted of the following amounts on the dates set forth below:

	December 31, 2009			June 30, 2010
Billed	$	273,994		$	257,330
Unbilled		161,600			148,568
Allowance for doubtful accounts		(5,924	)		(6,825	)
Total accounts receivable and unbilled services, net	$	429,670		$	399,073

5. Property and Equipment

Property and equipment, stated at cost, consisted of the following amounts on the dates set forth below:

	December 31, 2009			June 30, 2010
Land	$	8,299		$	8,083
Buildings and leasehold improvements		259,186			259,805
Fixed assets not placed in service		24,086			20,609
Information technology systems under development		10,102			18,054
Furniture and equipment		222,649			223,483
Computer equipment and software		203,447			200,924
Total property and equipment		727,769			730,958
Less accumulated depreciation		(339,310	)		(357,679	)
Total property and equipment, net	$	388,459		$	373,279

As of June 30, 2010, fixed assets not placed in service included software licenses purchased from a third-party vendor with annual payment terms as follows:

June 1, 2011	$	4,212
June 1, 2012		4,212
Total future remaining payments	$	8,424
Present value discount		(362	)
Present value of remaining payments	$	8,062

The Company classified its liability related to these licenses as $4.1 million in other accrued expenses and $4.0 million in other long-term liabilities on its consolidated condensed balance sheet as of June 30, 2010.

13

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(numbers in tables in thousands)

(unaudited)

6. Goodwill and Intangible Assets

Changes in the carrying amount of goodwill for the six months ended June 30, 2010, by operating segment, were as follows:

	Development			Discovery Sciences			Total
Balance as of December 31, 2009	$	276,737		$	46,646		$	323,383
Goodwill recorded during the period for acquisitions		1,373			—			1,373
Spin-off of Furiex Pharmaceuticals, Inc.		—			(46,646	)		(46,646	)
Translation adjustments		(9,235	)		—			(9,235	)
Balance as of June 30, 2010	$	268,875		$	—		$	268,875

The Company’s intangible assets were composed of the following as of the dates set forth below:

	December 31, 2009							June 30, 2010
	Carrying Amount		Accumulated Amortization			Net		Carrying Amount		Accumulated Amortization			Net
Backlog and customer relationships	$	24,657	$	(2,342	)	$	22,315	$	24,595	$	(4,208	)	$	20,387
Other intangible asset		2,000		—			2,000		2,000		—			2,000
Total	$	26,657	$	(2,342	)	$	24,315	$	26,595	$	(4,208	)	$	22,387

Intangible assets consist of backlog and customer relationships and an other intangible asset. The Company amortizes backlog and customer relationships on a straight-line basis, based on an estimated useful life of two to ten years. The weighted-average amortization period is 6.5 years for backlog and customer relationships. The other intangible asset has an indefinite life, and therefore, the Company does not amortize this asset.

Amortization expense for the three months ended June 30, 2009 and 2010 was $0.5 million and $0.9 million, respectively. Amortization expense for the six months ended June 30, 2009 and 2010 was $0.7 million and $1.9 million, respectively. As of June 30, 2010, expected amortization expense for each of the next five years is as follows:

2010 (remaining six months)	$	1,858
2011		3,600
2012		2,968
2013		2,791
2014		2,051

14

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(numbers in tables in thousands)

(unaudited)

7. Shareholders’ Equity

The Company measures share-based compensation cost at grant date, based on the fair value of the award, and recognizes it as expense over the employee’s requisite service period.

During the six months ended June 30, 2010, the Company granted options to purchase approximately 2,716,000 shares with a weighted-average exercise price of $23.30. All options were granted with an exercise price equal to the fair value of the Company’s common stock on the grant date. The fair value of the Company’s common stock on the grant date is equal to the Nasdaq closing price of the Company’s stock on the date of grant. The weighted-average grant date fair value per share determined using the Black-Scholes option-pricing method and the aggregate fair value of options granted during the six months ended June 30, 2009 and 2010 was $6.41 and $5.91 and $10.0 million and $16.0 million, respectively. As of June 30, 2010, the Company had 11.8 million options outstanding.

As a result of automatic plan adjustments triggered by the Furiex spin-off, the Company issued options to purchase approximately 300,500 additional shares not included in the total above. The per share exercise price of each outstanding option was adjusted to be equal to the product of the pre-distribution option exercise price multiplied by a fraction, the numerator of which was the Company’s closing price of its stock on the day of distribution and the denominator of which was the closing price of the Company’s stock plus the closing price of Furiex’s stock on the day of distribution. Following this adjustment to the per share exercise price, the number of shares subject to each outstanding option were adjusted to ensure that the intrinsic value of each option was the same on the day after the distribution as it was on the day of the distribution.

8. Comprehensive Income

Comprehensive income consisted of the following amounts on the dates set forth below:

	Three Months Ended June  30,					Six Months Ended June  30,
	2009		2010			2009		2010
Net income, as reported	$	58,061	$	20,977		$	102,630	$	38,182
Other comprehensive income (loss):
Cumulative translation adjustment		22,100		(20,542	)		13,478		(32,452	)
Change in fair value of hedging transaction, net of tax (expense) benefit of ($5,459), $244, ($5,196) and $1,456, respectively		12,473		(1,130	)		11,573		(3,984	)
Reclassification adjustment for hedging results included in direct costs, net of tax (expense) benefit of ($459), $253, ($1,845) and $936, respectively		876		(312	)		4,548		(1,561	)
Net unrealized gain (loss) on investments, net of tax expense of ($564), ($217), ($3,694) and ($1,162), respectively		1,027		391			6,711		2,233
Total other comprehensive income (loss)		36,476		(21,593	)		36,310		(35,764	)
Comprehensive income (loss)	$	94,537	$	(616	)	$	138,940	$	2,418

15

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(numbers in tables in thousands)

(unaudited)

8. Comprehensive Income

Accumulated other comprehensive loss consisted of the following amounts on the dates set forth below:

	December 31, 2009			June 30, 2010
Translation adjustment	$	9,951		$	(22,501	)
Pension liability, net of tax benefit of $5,876		(13,778	)		(13,778	)
Fair value on hedging transactions, net of tax expense of ($2,792) and ($411), respectively		5,554			9
Net unrealized loss on investments, net of tax benefit of $7,434 and $6,273, respectively		(13,692	)		(11,459	)
Total	$	(11,965	)	$	(47,729	)

9. Accounting for Derivative Instruments and Hedging Activities

The Company has significant international revenues and expenses, and related receivables and payables, denominated in foreign currencies. As a result, the Company’s operating results can be affected by movements in foreign currency exchange rates. In an effort to minimize this risk, from time to time, the Company purchases foreign currency option and forward contracts as cash flow hedges against anticipated and recorded transactions, and the related receivables and payables denominated in foreign currencies. The Company only uses foreign currency option and forward contracts as hedges to minimize the variability in the Company’s operating results arising from foreign currency exchange rate movements, and not for speculative or trading purposes.

The Company enters into foreign exchange derivatives that are designated and qualify as cash flow hedges of forecasted revenue and expense transactions. The Company recognizes changes in the fair value of the effective portion of these outstanding contracts in accumulated other comprehensive income, or OCI. The Company reclassifies these amounts from OCI and recognizes them in earnings when either the forecasted transaction occurs or it becomes probable that the forecasted transaction will not occur. The Company reclassifies OCI associated with hedges of foreign currency revenue into direct costs upon recognition of the forecasted transaction in the statements of income.

The Company recognizes changes in the ineffective portion of a derivative instrument in earnings in the current period as a component of direct costs. The Company measures effectiveness for forward cash flow hedge contracts by comparing the fair value of the forward contract to the change in the forward value of the anticipated transaction. The Company’s hedging portfolio ineffectiveness during the three months ended June 30, 2009 and 2010 was $0.1 million and $0.4 million, respectively. The Company’s hedging portfolio ineffectiveness during the six months ended June 30, 2009 and 2010 was $0.2 million.

The Company also manages its exposure on receivables and payables denominated in foreign currencies other than the entity’s functional currency through the use of natural hedges and foreign currency options and forwards, if necessary. The foreign currency derivatives are recorded at fair value, with fluctuations in the fair value being included in the statements of income. There were no outstanding foreign currency options and forwards related to receivables and payables hedging outstanding as of June 30, 2010 and the gains and losses reported in the statements of income were not significant.

As of June 30, 2010, the Company’s existing hedging contracts were scheduled to expire over the next 18 months. The Company expects to reclassify the current gain positions of approximately $1,000, net of tax, within the next 12 months from OCI into the statement of income. At December 31, 2009 and June 30, 2010, the Company’s foreign currency derivative portfolio resulted in the Company recognizing an asset of $9.0 million and $3.3 million, respectively, as a component of other current assets and a liability of $0.6 million and $3.2 million, respectively, as a component of other accrued expenses.

16

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(numbers in tables in thousands)

(unaudited)

10. Pension Plan

The Company has a contributory defined benefit plan for its qualifying United Kingdom, or U.K., employees employed by the Company’s U.K. subsidiaries. This pension plan was closed to new participants as of December 31, 2002. In December 2009, the Company amended the plan effective January 1, 2010. Participants are entitled to receive benefits previously accrued, which are based on the expected pay at retirement and number of years of service through January 1, 2010, but will receive no additional credit for future years of service. Plan assets consist principally of equities, bonds and cash managed in a mixed fund.

Pension costs for the U.K. pension plan included the following components on the dates set forth below:

	Three Months Ended June  30,						Six Months Ended June  30,
	2009			2010			2009			2010
Service cost	$	268		$	—		$	517		$	—
Interest cost		636			764			1,225			1,563
Expected return on plan assets		(465	)		(595	)		(896	)		(1,218	)
Amortization of losses		243			255			469			522
Net periodic pension cost	$	682		$	424		$	1,315		$	867

11. Commitments and Contingencies

The Company currently maintains insurance for risks, associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company’s retentions and deductibles associated with these insurance policies range in amounts up to $5.0 million.

The Company is self-insured for health insurance for the majority of its employees located within the United States, but maintains stop-loss insurance on a “claims made” basis for expenses in excess of $0.3 million per member per year. As of December 31, 2009 and June 30, 2010, the Company maintained a reserve of approximately $2.9 million and $2.1 million, respectively, included in other accrued expenses on the consolidated condensed balance sheets, to cover open claims and estimated claims incurred but not reported.

As of June 30, 2010, the Company had commitments to invest up to an aggregate additional $12.8 million in four venture capital funds, $2.1 million in other investments and $70.0 million in an equity method investment. For further details, see Note 3.

17

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(numbers in tables in thousands)

(unaudited)

11. Commitments and Contingencies

As of June 30, 2010, the Company’s total gross unrecognized tax benefits were $30.3 million, of which $15.7 million, if recognized, would reduce its effective tax rate. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits could decrease by up to $4.7 million within the next twelve months due to the settlement of audits and the expiration of statutes of limitations.

The Company’s policy for recording interest and penalties associated with tax audits is to record them as a component of provision for income taxes. For the six months ended June 30, 2010, the Company recorded $0.7 million and $0.1 million, respectively, of interest and penalties as expense in its statement of income. As of June 30, 2010, the Company accrued $6.0 million of interest and $1.1 million of penalties with respect to uncertain tax positions. To the extent interest and penalties are not assessed with respect to uncertain tax positions, the Company will reduce amounts accrued and reflect them as a reduction of the overall income tax provision.

In 2010, the Company entered into a non-revolving line of credit agreement to loan Celtic Pharma Development Services Bermuda Ltd., a subsidiary of Celtic Pharmaceutical Holdings L.P., up to $18.0 million for trade payables in connection with a specified drug candidate. Celtic Pharma Development Services Bermuda Ltd. has appointed the Company to conduct certain clinical studies on the specified drug candidate. Principal and interest are due and payable no later than June 30, 2013 and are secured by a guarantee of an affiliate of the borrower. As of June 30, 2010, the Company had advanced $4.0 million to the borrower and recorded this as a component of other assets.

Under most of the agreements for Development services, the Company typically agrees to indemnify and defend the sponsor against third-party claims based on the Company’s negligence or willful misconduct. Any successful claims could have a material adverse effect on the Company’s financial condition, results of operations or cash flows.

In the normal course of business, the Company is a party to various claims and legal proceedings. The Company records a reserve for pending and threatened litigation matters when an adverse outcome is probable and the amount of the potential liability is reasonably estimable. Although the ultimate outcome of pending and threatened litigation is currently not determinable and litigation costs can be material, management of the Company, after consultation with legal counsel, does not believe that the resolution of these matters will have a material effect upon the Company’s financial condition, results of operations or cash flows.

18

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(numbers in tables in thousands)

(unaudited)

12. Fair Value of Financial Instruments

The accounting standards related to fair value establish a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:

• Level 1 – Valuations based on quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Items valued using Level 1 inputs include money market funds, U.S. treasury securities and exchange-traded equity securities.

• Level 2 – Valuations based on quoted prices in markets that are not active, or for which all significant inputs are not observable, either directly or indirectly. Items valued using Level 2 inputs include derivatives and corporate and municipal debt securities.

• Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement. Items valued using Level 3 inputs include auction rate securities.

Level 2 valuations include the use of matrix pricing models, quotes for comparable securities and valuation models using observable market inputs. The Company measures its auction rate securities using models that use unobservable inputs such as the anticipated time to market liquidity and appropriate rates of return for comparable securities.

The following table presents information about the Company’s assets and liabilities required to be measured at fair value on a recurring basis:

	Level 1		Level 2		Level 3		Total
As of December 31, 2009
Assets
Money market funds	$	180,421	$	—	$	—	$	180,421
Short-term investments:
Treasury securities		95,932		—		—		95,932
Municipal debt securities		—		36,000		—		36,000
Corporate debt securities		9,165		3,548		—		12,713
Long-term investments		—		—		88,558		88,558
Derivative contracts		—		9,004		—		9,004
Total assets	$	285,518	$	48,552	$	88,558	$	422,628
Liabilities
Derivative contracts	$	—	$	611	$	—	$	611
Total liabilities	$	—	$	611	$	—	$	611

19

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(numbers in tables in thousands)

(unaudited)

12. Fair Value of Financial Instruments

	Level 1		Level 2		Level 3		Total
As of June 30, 2010
Assets
Money market funds	$	225,510	$	—	$	—	$	225,510
Short-term investments:
Treasury securities		9,258		—		—		9,258
Auction rate securities		6,800		—		—		6,800
Municipal debt securities		—		29,265		—		29,265
Corporate debt securities		—		12,733		—		12,733
Long-term investments		—		—		83,010		83,010
Derivative contracts		—		3,343		—		3,343
Total assets	$	241,568	$	45,341	$	83,010	$	369,919
Liabilities
Derivative contracts	$	—	$	3,170	$	—	$	3,170
Total liabilities	$	—	$	3,170	$	—	$	3,170

The following table provides a reconciliation of the beginning and ending balances for assets and liabilities measured at fair value using significant unobservable inputs (Level 3) for the six months ended June 30, 2010:

	Long-term investments
Balance as of December 31, 2009	$	88,558
Liquidation of investments		(1,325	)
Decrease in unrealized loss on investments included in other comprehensive income		2,801
Balance as of March 31, 2010	$	90,034
Transfers out of Level 3		(6,800	)
Liquidation of investments		(575	)
Decrease in unrealized loss on investments included in other comprehensive income		351
Balance as of June 30, 2010	$	83,010

Transfers out of Level 3 represent assets reclassified to Level 1 securities as the result of market activity which provided observable inputs for valuation during the period. Transfers out of Level 3 are measured at the end of the period.

20

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(numbers in tables in thousands)

(unaudited)

13. Business Segment Data

Revenue by principal business segment is separately stated in the consolidated condensed financial statements. Operating income and identifiable assets by principal business segment were as follows as of the dates set forth below:

	Three Months Ended June  30,						Six Months Ended June  30,
	2009			2010			2009		2010
Operating income (loss):
Development	$	58,941		$	43,086		$	121,552	$	79,626
Discovery Sciences		(677	)		(3,002	)		3,300		(11,860	)
Total	$	58,264		$	40,084		$	124,852	$	67,766
							December 31, 2009		June 30, 2010
Identifiable assets:
Development							$	1,969,103	$	1,845,707
Discovery Sciences								61,100		—
Total							$	2,030,203	$	1,845,707

14. Spin-off of Furiex Pharmaceuticals, Inc.

On June 14, 2010, the Company spun off its compound partnering business. Substantially all of the operating business components of the Discovery Sciences segment were included in the spin-off. The Company contributed substantially all of assets and liabilities of the Discovery Sciences segment and $100.0 million of cash and cash equivalents to Furiex Pharmaceuticals, Inc. All outstanding shares of Furiex were then distributed to the Company’s shareholders of record on June 1, 2010 as a pro-rata, tax-free dividend of one share of Furiex common stock for every twelve shares of the Company’s common stock.

In connection with the spin-off, the Company and Furiex entered into a series of agreements, including a separation and distribution agreement, transition services agreement, sublease and license agreements, employee matters agreement, tax sharing agreement and a master development services agreement.

The total amount of the Furiex stock dividend was $146.7 million. This amount was based on the net book value of the net assets that were contributed to Furiex in connection with the spin-off, as follows:

	2010
Net book value of assets transferred:
Cash and cash equivalents	$	100,000
Accounts receivable		7,705
Prepaid expenses		100
Property and equipment, net		18
Goodwill		46,646
Accounts payable		(758	)
Accrued expenses and other current liabilities		(3,545	)
Long-term liabilities		(3,502	)
Net assets transferred	$	146,664

Furiex’s historical results of operations have been presented as continuing operations in the consolidated condensed statements of income as the Company deemed that this transaction did not qualify for discontinued operations due to the continuation of the master development services agreement between PPD and Furiex.

21

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis is provided to increase understanding of, and should be read in conjunction with, our consolidated condensed financial statements and accompanying notes. In this discussion, the words “PPD”, “we”, “our” and “us” refer to Pharmaceutical Product Development, Inc., together with its subsidiaries where appropriate.

Forward-looking Statements

This Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. These statements relate to future events or our future financial performance. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, expectations, predictions, assumptions and other statements that are not statements of historical facts. In some cases, you can identify forward-looking statements by terminology such as “might”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “intend”, “potential” or “continue”, or the negative of these terms, or other comparable terminology. These statements are only predictions. These statements rely on a number of assumptions and estimates that could be inaccurate and that are subject to risks and uncertainties. Actual events or results might differ materially due to a number of factors, including those listed in “Potential Volatility of Quarterly Operating Results and Stock Price” below and in “Item 1A. Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2009. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Company Overview

We are a leading global contract research organization providing drug discovery and development services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. Our corporate mission is to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize returns on their research and development investments.

We have been in the drug development business for more than 25 years. Our development services include preclinical programs and Phase I through Phase IV clinical development services, as well as bioanalytical, cGMP, global central laboratory and vaccines and biologics laboratory services. We have extensive clinical trial experience, including regional, national and global studies across a wide spectrum of therapeutic areas and in 102 countries spanning six continents. In addition, for marketed drugs, biologics and devices, we offer support such as product launch services, medical information, patient compliance programs, patient and disease registry programs, product safety and pharmacovigilance, Phase IV monitored studies and prescription-to-over-the-counter, or Rx to OTC, programs.

With 85 offices in 41 countries and more than 10,500 employees worldwide, we have provided services to 49 of the top 50 pharmaceutical companies in the world as ranked by 2008 healthcare research and development spending. We also work with leading biotechnology companies and government organizations that sponsor clinical research. We are one of the world’s largest providers of drug development services based on 2009 annual net revenue generated from contract research organizations.

Building on our outsourcing relationship with pharmaceutical and biotechnology clients, we established our Discovery Sciences business in 1997. This business primarily focused on compound development and commercialization collaborations. As previously announced, we spun off this business to our shareholders in a new public company, Furiex Pharmaceuticals, Inc., in June 2010.

Our development services offer our clients a way to identify and develop drug candidates more quickly and cost-effectively. In addition, with global infrastructure, we are able to accommodate the multinational drug discovery and development needs of our clients. For more detailed information on PPD, see our Annual Report on Form 10-K for the year ended December 31, 2009.

22

Executive Overview

Our revenues depend on a relatively small number of industries and clients. As a result, we closely monitor the market for our services. For a discussion of the trends affecting the market for our services, see “Item 1. Business – Industry Overview – Trends Affecting the Drug Discovery and Development Industry” in our Annual Report on Form 10-K for the year ended December 31, 2009. In the first half of 2010, we experienced higher demand for our services and lower cancellation rates than we experienced during 2009, which was a difficult year. We continue to believe in the fundamentals of the market and that it will rebound in future periods. For the remainder of 2010, we plan to focus on sales execution, operational performance and building strategic relationships with pharmaceutical and biotechnology companies.

We continue to integrate the companies we acquired in 2009 into our operations. In November 2009, we acquired Excel PharmaStudies, Inc., one of the largest CROs in China. Excel is headquartered in Beijing, China and has offices in more than 15 cities throughout China. With this acquisition we strengthened our global footprint, significantly expanded our presence and reach within China and improved our ability to offer Phase II-IV clinical, data management, biostatistics and regulatory services on a global basis. Shortly after acquiring Excel, we completed our acquisition of BioDuro LLC, a drug discovery services company that provides a broad range of integrated drug discovery services to biopharmaceutical companies. BioDuro operates a state-of-the-art, 110,000 square foot facility in Beijing, China and provides fully integrated programs to synthesize and optimize novel compounds to generate drug development candidates. The acquisition of BioDuro expanded our spectrum of service offerings. In 2010, we launched our Vaccine and Biologics Center of Excellence, which is focused specifically on the development of vaccines, monoclonal antibodies, peptides, protein-drug conjugates and other biologics.

We review various metrics to evaluate our financial performance, including period-to-period changes in backlog, new authorizations, cancellation rates, revenue, margins and earnings. In the second quarter of 2010, we had net authorizations of $465.2 million, an increase of 83.9% over the same period in 2009. The cancellation rate for the second quarter of 2010 was 4.5% of backlog, compared to 6.7% for the same period in 2009. As of June 30, 2010, backlog was $3.2 billion, up 7.2% from December 31, 2009. The average length of our contracts in backlog decreased to 35 months as of June 30, 2010 from 37 months as of June 30, 2009.

Backlog by client type as of June 30, 2010 was 78.1% pharmaceutical, 15.2% biotech and 6.7% government/other, as compared to 65.4% pharmaceutical, 25.8% biotech and 8.8% government/other as of June 30, 2009. Net revenue by client type for the quarter ended June 30, 2010 was 77.3% pharmaceutical, 17.7% biotech and 5.0% government/other, compared to 59.7% pharmaceutical, 29.0% biotech and 11.3% government/other for the quarter ended June 30, 2009. This change in the composition of our backlog and net revenue is primarily a result of an increase in the percentage of authorizations from pharmaceutical companies during the twelve-month period ended June 30, 2010 and mergers of biotechnology clients into pharmaceutical companies.

For the second quarter of 2010, net revenue contribution by service area for our Development segment was 76.5% for Phase II-IV services, 19.1% for laboratory services and 4.4% for the Phase I clinic, compared to 78.8% for Phase II-IV services, 17.5% for laboratory services and 3.7% for the Phase I clinic for the same period in 2009. Our top therapeutic areas by net revenue for the quarter ended June 30, 2010 were oncology, circulatory/cardiovascular, endocrine/metabolic, infectious diseases and central nervous system. For a detailed discussion of our revenue, margins, earnings and other financial results for the quarter ended June 30, 2010, see “Results of Operations – Three Months Ended June 30, 2009 versus Three Months Ended June 30, 2010” below.

Our operating margin rate for the second quarter of 2010 was 10.8% and reflects investments we have made in our Phase II-IV business, overhead and integration expenses from our acquisitions of Excel and Bioduro in China, start-up expenses associated with our new cGMP lab in Ireland and call center in Eastern Europe, and investments in information technology and business development. We anticipate continuing improvement in operating margin during the course of 2010 from projected revenue growth and return on our investments. We continue to focus on all selling, general and administrative, or SG&A, spending and driving efficiencies, while selectively investing for future growth and productivity gains.

23

Capital expenditures for the three months ended June 30, 2010 totaled $16.0 million. These capital expenditures were primarily for computer hardware and software, scientific equipment for our laboratory units and various leasehold improvements. We made these investments to support our business and to improve the efficiencies of our operations. For the remainder of 2010, we expect to spend between approximately $30 million to $55 million for capital expenditures, primarily for facility expansions and improvements, as well as investments in information technology and new laboratory equipment.

As of June 30, 2010, we had $575.1 million of cash, cash equivalents and short- and long-term investments. In the second quarter of 2010, we generated $59.5 million in cash from operations. The number of days’ revenue outstanding in accounts receivable and unbilled services, net of unearned income, also known as DSO, was 23 days for the six months ended June 30, 2010, compared to 31 days for the year ended December 31, 2009. DSO decreased in the second quarter of 2010 due to improved cash collections, the mix of contracts performed and their payment terms. We plan to continue to monitor DSO and the various factors that affect it. However, we expect DSO will continue to fluctuate from quarter to quarter depending on contract terms, the mix of contracts performed and our success in collecting receivables.

As previously announced, in June 2010, we spun off our compound partnering business into a separate, independent, publicly traded company, Furiex Pharmaceuticals, Inc.

New Business Authorizations and Backlog

We add new business authorizations, which are sales of our services, to backlog when we enter into a contract or letter of intent or receive a verbal commitment. Authorizations can vary significantly from quarter to quarter and contracts generally have terms ranging from several months to several years. We recognize revenue on these authorizations as services are performed. Our new authorizations for the three months ended June 30, 2009 and 2010 were $465.9 million and $610.5 million, respectively.

Our backlog consists of anticipated net revenue from contracts, letters of intent and verbal commitments that either have not started but are anticipated to begin in the future, or are in process and have not been completed. As of June 30, 2010, the remaining duration of the contracts in our backlog ranged from one to 100 months, with a weighted-average duration of 35 months. We expect the weighted-average duration of the contracts in our backlog to fluctuate from quarter to quarter in the future, based on the contracts constituting our backlog at any given time. Amounts included in backlog represent anticipated future net revenue, exclude net revenue that has been recognized previously in our statements of income, and have been adjusted for foreign currency fluctuations. Our backlog as of June 30, 2009 and 2010 was $3.2 billion. For various reasons discussed in “Item 1. Business – Backlog” in our Annual Report on Form 10-K for the year ended December 31, 2009, including contract cancellations, our backlog might never be recognized as revenue and is not necessarily a meaningful predictor of future performance.

Results of Operations

Revenue Recognition

We record revenue from contracts, other than time-and-material contracts, on a proportional performance basis in our Development and Discovery Sciences segments. To measure performance on a given date, we compare direct costs through that date to estimated total direct costs to complete the contract. Direct costs relate primarily to the amount of labor and related overhead costs for the delivery of services. We believe this is the best indicator of the performance of the contractual obligations. Changes in the estimated total direct costs to complete a contract without a corresponding proportional change to the contract value result in a cumulative adjustment to the amount of revenue recognized in the period the change in estimate is determined. For time-and-material contracts in both our Development and Discovery Sciences segments, we recognize revenue as hours are worked, multiplied by the applicable hourly rate. For our Phase I and laboratory businesses, we recognize revenue from unitized contracts as subjects or samples are tested, multiplied by the applicable unit price. We offer volume discounts to our large customers based on annual volume thresholds. We record an estimate of the annual volume rebate as a reduction of revenue throughout the period based on the estimated total rebate to be earned for the period.

24

In connection with the management of clinical trials, we pay, on behalf of our clients, fees to investigators and test subjects as well as other out-of-pocket costs for items such as travel, printing, meetings and couriers. Our clients reimburse us for these costs. Amounts paid by us as a principal for out-of-pocket costs are included in direct costs as reimbursable out-of-pocket expenses and the reimbursements we receive as a principal are reported as reimbursed out-of-pocket revenue. In our statements of income, we combine amounts paid by us as an agent for out-of-pocket costs with the corresponding reimbursements, or revenue, we receive as an agent. During the three months ended June 30, 2009 and 2010, fees paid to investigators and other fees we paid as an agent and the associated reimbursements were approximately $97.1 million and $91.3 million, respectively.

Most of our contracts can be terminated by our clients either immediately or after a specified period following notice. These contracts typically require the client to pay us the fees earned to date, the fees and expenses to wind down the study and, in some cases, a termination fee or some portion of the fees or profit that we could have earned under the contract if it had not been terminated early. Therefore, revenue recognized prior to cancellation generally does not require a significant adjustment upon cancellation. If we determine that a loss will result from the performance of a contract, we charge the entire amount of the estimated loss against income in the period in which such determination is made.

The Discovery Sciences segment generated revenue in the form of upfront payments, development and regulatory milestone payments, royalties and sales-based milestone payments in connection with the out-licensing of compounds. Upfront payments were generally paid within a short period of time following the execution of an out-license and collaboration agreement. Milestone payments were typically one-time payments to us triggered by the collaborator’s achievement of specified development and regulatory events such as the commencement of Phase III trials or regulatory submission or approval. Royalties were payments received by us based on net product sales of a collaboration. Sales-based milestone payments were typically one-time payments to us triggered when the aggregate net sales of product by a collaborator for a specified period (for example, an annual period) reach an agreed upon threshold amount. We recognized these various forms of payment from our collaborators when the event which triggered the obligation of payment had occurred, there were no further obligations on our part in connection with the payment, and collection was reasonably assured.

Recording of Expenses

We generally record our operating expenses among the following categories:

• direct costs;

• research and development;

• selling, general and administrative; and

• depreciation and amortization.

Direct costs consist of amounts necessary to carry out the revenue and earnings process, and include direct labor and related benefit charges, other costs directly related to contracts, an allocation of facility and information technology costs, and reimbursable out-of-pocket expenses. Direct costs, as a percentage of net revenue, tend to and are expected to fluctuate from one period to another as a result of changes in labor utilization and the mix of service offerings involved in the hundreds of studies being conducted during any period of time.

Research and development, or R&D, expenses consist primarily of labor and related benefit charges associated with personnel performing internal research and development work, supplies associated with this work, consulting services and an allocation of facility and information technology costs.

SG&A expenses consist primarily of administrative payroll and related benefit charges, sales, advertising and promotional expenses, recruiting and relocation expenses, training costs, administrative travel, an allocation of facility and information technology costs and costs related to operational employees performing administrative tasks.

We record property and equipment at cost less accumulated depreciation. We record depreciation expense on a straight-line method, based on the following estimated useful lives:

Buildings	20-40 years
Furniture and equipment	5-10 years
Computer equipment and software	2-5 years
Aircraft	30 years

25

We depreciate leasehold improvements over the shorter of the respective lives of the leases or the useful lives of the improvements. We depreciate property under capital leases over the term of the lease or the service life, whichever is shorter.

Three Months Ended June 30, 2009 versus Three Months Ended June 30, 2010

The following table sets forth amounts from our consolidated condensed financial statements along with the dollar and percentage change for the three months ended June 30, 2009 compared to the three months ended June 30, 2010.

	Three Months Ended June 30,
(in thousands, except per share data)	2009		2010			$ Inc (Dec)			% Inc (Dec)
Net revenue:
Development	$	330,179	$	333,779		$	3,600		1.1	%
Discovery Sciences		162		7,717			7,555		4,663.6
Reimbursed out-of-pockets		24,257		28,423			4,166		17.2
Total net revenue		354,598		369,919			15,321		4.3
Direct costs:
Development		158,486		163,773			5,287		3.3
Discovery Sciences		145		(26	)		(171	)	(117.9	)
Reimbursable out-of-pocket expenses		24,257		28,423			4,166		17.2
Total direct costs		182,888		192,170			9,282		5.1
Research and development expenses		979		8,445			7,466		762.6
Selling, general and administrative expenses		96,648		112,106			15,458		16.0
Depreciation and amortization		15,819		17,114			1,295		8.2
Operating income		58,264		40,084			(18,180	)	(31.2	)
Loss from equity method investment		—		(1,747	)		(1,747	)	(100.0	)
Other income, net		1,075		2,747			1,672		155.5
Income from continuing operations before provision for income taxes		59,339		41,084			(18,255	)	(30.8	)
Provision for income taxes		17,894		17,522			(372)		(2.1)
Income from continuing operations		41,445		23,562			(17,883	)	(43.1	)
Income (loss) from discontinued operations, net of provision for income taxes		16,616		(2,585)			(19,201)		(115.6)
Net income	$	58,061	$	20,977		$	(37,084	)	(63.9	)
Income per diluted share from continuing operations	$	0.35	$	0.20		$	(0.15	)	(42.9	)
Income (loss) per diluted share from discontinued operations	$	0.14	$	(0.02	)	$	(0.16	)	(114.3	)
Net income per diluted share	$	0.49	$	0.18		$	(0.31	)	(63.3	)

26

Total net revenue increased $15.3 million to $369.9 million in the second quarter of 2010. The increase in total net revenue resulted from increases in both our Development and Discovery Sciences segment revenue. The Development segment generated net revenue of $333.8 million, which accounted for 90.2% of total net revenue for the second quarter of 2010. The $3.6 million increase in Development segment net revenue was primarily attributable to a $8.2 million increase in net revenue from our laboratory units and our Phase I clinic, offset by a decrease of $4.6 million in our Phase II-IV services. Of the decrease in our Phase II-IV services, $2.6 million was due to the strengthening of the U.S. dollar relative to the euro and pound sterling. The increase in net revenue from our laboratory services was primarily related to the BioDuro acquisition in late 2009.

The Discovery Sciences segment generated net revenue of $7.7 million in the second quarter of 2010. The $7.6 million increase in Discovery Sciences segment net revenue from the same period in 2009 was primarily attributable to the $7.5 million milestone payment we earned as a result of regulatory approvals of NESINA® in Japan. We contributed the account receivable for that payment to Furiex in the spin-off of our compound partnering business.

Total direct costs increased $9.3 million to $192.2 million in the second quarter of 2010 primarily as the result of an increase in Development segment direct costs. Development segment direct costs increased $5.3 million to $163.8 million in the second quarter of 2010. The increase was mainly attributable a $5.7 million reduction in research credits recognized in the second quarter of 2010 compared to the same period in 2009, an increase of $2.0 million in contract labor and subcontractor costs and an increase of $1.3 million in supply costs related to our laboratories. These costs were partially offset by a hedging gain of $0.5 million in the second quarter of 2010 compared to a hedging loss of $1.8 million in the second quarter of 2009, as well as a $1.6 million decrease in personnel costs.

R&D expenses increased $7.5 million to $8.4 million in the second quarter of 2010. The increase in R&D expense was primarily due to development costs associated with the two therapeutic compounds acquired from Janssen Pharmaceutica in November 2009. Given the completion of our spin-off of the compound partnering business in June 2010, we expect R&D expenses to decrease substantially over the remainder of 2010.

SG&A expenses increased $15.5 million to $112.1 million in the second quarter of 2010. The increase in SG&A expenses was primarily related to a $7.6 million increase in personnel costs primarily related to additional employees from the Excel and BioDuro acquisitions, a $4.9 million increase in facilities and information systems costs, $1.8 million in accounting and legal costs related to our compound partnering spin-off, a $1.3 million increase in non-billable travel, meals and entertainment costs and a $0.8 million increase in contract labor and subcontractor costs. These costs were partially offset by a $2.0 million decrease in bad debt expense.

Depreciation and amortization expense increased $1.3 million to $17.1 million in the second quarter of 2010. The increase was related to property and equipment we acquired to accommodate future growth.

In October 2009, we committed to invest up to $102.7 million in Celtic Therapeutics Holdings, L.P. As of June 30, 2010, we had invested a total of $32.7 million of the aggregate commitment. We account for this investment under the equity method of accounting. For the three months ended June 30, 2010, we recognized a loss from equity investment of $1.7 million. As of June 30, 2010, our investment balance in Celtic was $27.6 million.

Other income, net increased $1.7 million to $2.7 million in the second quarter of 2010. This increase was due primarily to a gain on sale of investment, partially offset by an impairment of investment.

Our provision for income taxes from continuing operations decreased $0.4 million to $17.5 million in the second quarter of 2010. Our effective income tax rate from continuing operations for the second quarter of 2010 was 42.6% compared to 30.2% for the second quarter of 2009. The increase in our effective tax rate was primarily attributable to $3.8 million of tax expense in the second quarter of 2010 related to a valuation allowance for deferred tax assets for the compound partnering spin-off.

The loss from discontinued operations, net of provision for income taxes was $2.6 million in the second quarter of 2010. In May 2009, we completed the disposition of substantially all of the assets of Piedmont Research Center, LLC. Piedmont Research Center provided preclinical research services. The gain from the sale of Piedmont Research Center of $19.5 million, net of provision for income taxes of $16.1 million was recognized in the second quarter of 2009. In December 2009, we completed the disposition of our wholly owned subsidiary PPD Biomarker Discovery Sciences, LLC. PPD Biomarker Discovery Sciences provided biomarker discovery services and participant sample analysis. In May 2010, we discontinued the operations of our wholly owned subsidiary PPD Dermatology, Inc. due to unfavorable efficacy data associated with the MAG-131 program. As a result, these business units have been shown as discontinued operations for 2009 and 2010.

27

Net income decreased $37.1 million to $21.0 million in the second quarter of 2010, a decrease of 63.9% from $58.1 million in the second quarter of 2009. Net income per diluted share of $0.18 in the second quarter of 2010 represents a 63.3% decrease from $0.49 net income per diluted share in the second quarter of 2009. Net income per diluted shares for the second quarter of 2009 included a $19.5 million gain, net of tax, from the sale of Piedmont Research Center.

Six Months Ended June 30, 2009 versus Six Months Ended June 30, 2010

The following table sets forth amounts from our consolidated condensed financial statements along with the dollar and percentage change for the six months ended June 30, 2009 compared to the six months ended June 30, 2010.

	Six Months Ended June 30,
(in thousands, except per share data)	2009		2010			$ Inc (Dec)			% Inc (Dec)
Net revenue:
Development	$	665,533	$	657,606		$	(7,927	)	(1.2	%)
Discovery Sciences		5,324		8,010			2,686		50.5
Reimbursed out-of-pockets		48,111		51,072			2,961		6.2
Total net revenue		718,968		716,688			(2,280	)	(0.3	)
Direct costs:
Development		322,655		323,774			1,119		0.3
Discovery Sciences		440		126			(314	)	(71.4	)
Reimbursable out-of-pocket expenses		48,111		51,072			2,961		6.2
Total direct costs		371,206		374,972			3,766		1.0
Research and development expenses		2,290		14,783			12,493		545.5
Selling, general and administrative expenses		189,783		225,016			35,233		18.6
Depreciation and amortization		30,837		34,151			3,314		10.7
Income from operations		124,852		67,766			(57,086	)	(45.7	)
Loss from equity method investment		—		(3,789	)		(3,789	)	(100.0	)
Other income, net		857		4,020			3,163		369.1
Income from continuing operations before provision for income taxes		125,709		67,997			(57,712	)	(45.9	)
Provision for income taxes		39,124		26,153			(12,971	)	(33.2	)
Income from continuing operations		86,585		41,844			(44,741	)	(51.7	)
Income (loss) from discontinued operations, net of provision for income taxes		16,045		(3,662	)		(19,707	)	(122.8	)
Net income	$	102,630	$	38,182		$	(64,448	)	(62.8	)
Income per diluted share from continuing operations	$	0.73	$	0.35		$	(0.38	)	(52.1	)
Income (loss) per diluted share from discontinued operations	$	0.14	$	(0.03	)	$	(0.17	)	(121.4	)
Net income per diluted share	$	0.87	$	0.32		$	(0.55	)	(63.2	)

28

Total net revenue decreased $2.3 million to $716.7 million in the first six months of 2010. The decrease in total net revenue resulted from a decrease in our Development segment revenue, partially offset by an increase in Discovery Sciences segment revenue. The Development segment generated net revenue of $657.6 million, which accounted for 91.8% of total net revenue for the first six months of 2010. The $7.9 million decrease in Development segment net revenue was primarily attributable to a $23.4 million decrease in net revenue from our Phase II-IV services, offset by a $15.5 million increase in net revenue from our laboratory units and our Phase I clinic. The decrease in Phase II-IV services was related to the decrease in net authorizations in 2009. The increase in net revenue from our laboratory services was primarily related to the BioDuro acquisition in late 2009.

The Discovery Sciences segment generated net revenue of $8.0 million in the first six months of 2010, an increase of $2.7 million from the first six months of 2009. The higher 2010 Discovery Sciences segment net revenue was mainly attributable to the $7.5 million milestone payment we earned as a result of regulatory approvals of NESINA in Japan, while in 2009 we earned a $5.0 million in milestone payments as a result of regulatory approvals of Priligy in Finland and Sweden.

Total direct costs increased $3.8 million to $375.0 million in the first six months of 2010 primarily as the result of an increase in Development segment direct costs and reimbursable out-of-pocket expenses. Development segment direct costs increased $1.1 million to $323.8 million in the first six months of 2010. The increase was mainly attributable to a $3.0 million reduction in research credits recognized in the first six months of 2010 compared to the same period in 2009, a $3.7 million increase in supply costs related to our laboratories and a $1.2 million increase in facilities costs. These costs were partially offset by a hedging gain of $2.4 million in the first six months of 2010 compared to a hedging loss of $6.4 million in the first six months of 2009.

R&D expenses increased $12.5 million to $14.8 million in the first six months of 2010. The increase in R&D expense was primarily due to development costs associated with the two therapeutic compounds acquired from Janssen Pharmaceutica in November 2009. Given the completion of our spin-off of the compound partnering business in June 2010, we expect R&D expenses to decrease substantially over the remainder of 2010.

SG&A expenses increased $35.2 million to $225.0 million in the first six months of 2010. The increase in SG&A expenses was primarily related to a $16.9 million increase in personnel costs primarily related to additional employees related to the Excel and BioDuro acquisitions, a $6.9 million increase in facilities and information systems costs, $5.0 million in accounting and legal costs related primarily to our compound partnering spin-off, a $3.2 million increase in non-billable travel and training costs, a $3.0 million reduction in research credits recognized in the first six months of 2010 compared to the same period in 2009 and a $1.4 million increase in contract labor and subcontractor costs, partially offset by a decrease of $1.4 million in bad debt expense.

Depreciation and amortization expense increased $3.3 million to $34.2 million in the first six months of 2010. The increase relates to property and equipment we acquired over the past year to accommodate growth.

In October 2009, we committed to invest up to $102.7 million in Celtic Therapeutics Holdings, L.P. As of June 30, 2010, we had invested a total of $32.7 million of the aggregate commitment. We account for this investment under the equity method of accounting. For the six months ended June 30, 2010, we recognized a loss from equity investment of $3.8 million. As of June 30, 2010, our investment balance in Celtic was $27.6 million.

Other income, net increased $3.2 million to $4.0 million in the first six months of 2010. Changes in exchange rates from the time we recognize revenue until the client pays resulted in a net loss of $0.2 million for the first six months of 2010, down from a net loss of $2.4 million for the first six months of 2009. The increase in other income was also due to a gain on sale of investment, partially offset by an impairment of investment and a decrease in interest income from lower rates earned on cash balances.

Our provision for income taxes from continuing operations decreased $13.0 million to $26.2 million in the first six months of 2010. Our effective income tax rate from continuing operations for the first six months of 2010 was 38.5% compared to 31.1% for the first six months of 2009. The increase in our effective tax rate was primarily attributable to $3.8 million of tax expense in the first six months of 2010 related to a valuation allowance for deferred tax assets for the compound partnering spin-off.

29

The loss from discontinued operations, net of provision for income taxes was $3.7 million in the first six months of 2010. In May 2009, we completed the disposition of substantially all of the assets of Piedmont Research Center, LLC. Piedmont Research Center provided preclinical research services. The gain from the sale of Piedmont Research Center of $19.5 million, net of provision for income taxes of $16.1 million was recognized in the first six months of 2009. In December 2009, we completed the disposition of our wholly owned subsidiary PPD Biomarker Discovery Sciences, LLC. PPD Biomarker Discovery Sciences provided biomarker discovery services and participant sample analysis. In May 2010, we discontinued the operations of our wholly owned subsidiary PPD Dermatology, Inc. due to unfavorable efficacy data associated with the MAG-131 program. As a result, these business units have been shown as discontinued operations for 2009 and 2010.

Net income of $38.2 million in the first six months of 2010 represents a decrease of 62.8% from $102.6 million in the first six months of 2009. Net income per diluted share of $0.32 in the first six months of 2010 represents a 63.2% decrease from $0.87 net income per diluted share in the first six months of 2009. Net income per diluted share for the first six months of 2009 included $5.0 million in milestone payments in connection with the regulatory approvals of Priligy in Finland and Sweden and a $19.5 million gain, net of tax, from the sale of Piedmont Research Center.

Liquidity and Capital Resources

As of June 30, 2010, we had $434.1 million of cash and cash equivalents and $58.1 million of short-term investments. We invest our cash and cash equivalents and short-term investments in bank deposits, financial instruments that are issued or guaranteed by the U.S. government and municipal debt obligations. Our expected primary cash needs are for capital expenditures, expansion of services, possible acquisitions, investments, geographic expansion, dividends, working capital and other general corporate purposes. We have historically funded our operations, dividends and growth, including acquisitions, primarily with cash flow from operations.

We held approximately $88.6 million and $89.8 million, net of unrealized loss, in auction rate securities at December 31, 2009 and June 30, 2010, respectively. Our portfolio of investments in auction rate securities consists principally of interests in government-guaranteed student loans, insured municipal debt obligations and municipal preferred auction rate securities. Except for $6.8 million sold in July 2010, the entire balance of auction rate securities were classified as long-term investments as of June 30, 2010 due to uncertainties about the liquidity in the auction rate securities market. We also recorded an unrealized loss on these investments of $21.3 million and $18.2 million as of December 31, 2009 and June 30, 2010, respectively. We concluded that this impairment was temporary because of our ability and intent to hold the auction rate securities until the fair value recovers. We will continue to seek to liquidate these investments at par value and will review the classification and valuation of these securities on a quarterly basis.

In the first six months of 2010, our operating activities provided $121.5 million in cash as compared to $81.9 million for the same period last year. The change in cash flow was due primarily to (1) lower net income in the first six months of 2010 compared to the same period in 2009, (2) a $20.6 million increase in noncash items relating to investing or financing activities, including a gain on sale of business of $19.5 million in the 2009 period, a net-of-tax loss from equity investment of $2.5 million, a $0.8 million impairment of investment, an increase in depreciation and amortization of $3.7 million, an increase in net loss on sale of assets of $1.5 million and an increase of $0.8 million on net gain on sale of investment, partially offset by a $7.0 million decrease in deferred income taxes and a $1.4 million decrease in the provision for doubtful accounts and (3) changes in operating cash receipts and payments totaling $83.4 million. The change in adjustments for accruals of expected future operating cash receipts and payments includes accounts receivable and unbilled services of $21.9 million, unearned income of $16.6 million, current income taxes of $21.7 million, accounts payable and other accrued expenses and deferred rent of $13.7 million, prepaid expenses and investigator advances of $9.6 million and payables to investigators of $2.3 million. The change in adjustments to deferrals of past operating cash receipts and payments includes other assets of ($2.3) million. Fluctuations in receivables and unearned income occur on a regular basis as we perform services, achieve milestones or other billing criteria, send invoices to clients and collect outstanding accounts receivable. This activity varies by individual client and contract. We attempt to negotiate payment terms that provide for payment of services prior to or soon after the provision of services, but the levels of unbilled services and unearned revenue can vary significantly from quarter to quarter.

30

In the first six months of 2010, our investing activities provided $53.0 million in cash. We used cash of $10.2 million to purchase investments, $27.2 million for capital expenditures, $7.2 million for acquisitions and $4.0 million for loan advances. These amounts were offset by maturity and sale of investments of $98.0 million and additional proceeds from the sale of business of $3.5 million. Our capital expenditures in the first six months of 2010 primarily consisted of $12.8 million for computer software and hardware, $8.0 million for additional scientific equipment for our laboratory units and $6.4 million for various facility improvements and furnishings.

In the first six months of 2010, our financing activities used $129.3 million of cash. We contributed $100.0 million of cash and cash equivalents to Furiex in the compound partnering spin-off and paid $35.6 million of dividends to shareholders, which were partially offset by proceeds of $6.1 million from stock option exercises and purchases under our employee stock purchase plan.

The following table sets forth amounts from our consolidated condensed balance sheet affecting our working capital, along with the dollar amount of the change from December 31, 2009 to June 30, 2010.

(in thousands)	December 31, 2009		June 30, 2010		$ Inc (Dec)
Current assets:
Cash and cash equivalents	$	408,903	$	434,074	$	25,171
Short-term investments		144,645		58,056		(86,589	)
Accounts receivable and unbilled services, net		429,670		399,073		(30,597	)
Income tax receivable		16,887		15,526		(1,361	)
Investigator advances		13,980		17,580		3,600
Prepaid expenses		24,458		26,533		2,075
Deferred tax assets		26,068		26,733		665
Cash held in escrow		12,415		16,889		4,474
Other current assets		55,115		31,358		(23,757	)
Total current assets	$	1,132,141	$	1,025,822	$	(106,319	)
Current liabilities:
Accounts payable	$	34,005	$	30,530	$	(3,475	)
Payables to investigators		54,428		52,099		(2,329	)
Accrued income taxes		4,043		5,748		1,705
Other accrued expenses		200,720		196,563		(4,157	)
Unearned income		297,844		300,532		2,688
Total current liabilities	$	591,040	$	585,472	$	(5,568	)
Working capital	$	541,101	$	440,350	$	(100,751	)

Working capital as of June 30, 2010 was $440.4 million, compared to $541.1 million at December 31, 2009. The decrease in working capital was due primarily to the contribution of $100.0 million of cash and cash equivalents to Furiex in the compound partnering spin-off.

For the six months ended June 30, 2010, DSO was 23 days compared to 31 days for the year ended December 31, 2009. We calculate DSO by dividing accounts receivable and unbilled services less unearned income by average daily gross revenue for the applicable period. We expect DSO will continue to fluctuate in the future depending on contract terms, the mix of contracts performed within a quarter, the levels of investigator advances and unearned income, and our success in collecting receivables.

Our $25.0 million revolving credit facility with Bank of America, N.A. expired on June 30, 2010 and was not subsequently renewed. As of June 30, 2010, no borrowings were outstanding under this credit facility.

In May 2009, our board of directors increased the annual dividend rate from $0.50 to $0.60 per share per year, payable quarterly at a rate of $0.15 per share effective beginning in the second quarter of 2009. The annual cash dividend policy and the payment of future quarterly cash dividends under that policy are not guaranteed and are subject to the discretion of and continuing determination by our board of directors that the policy remains in the best interests of our shareholders and in compliance with applicable laws and agreements.

31

In 2008, we announced that our board of directors approved a stock repurchase program authorizing us to repurchase up to $350.0 million of our common stock from time to time in the open market. As of June 30, 2010, $260.7 million remained available for share repurchases under the stock repurchase program. Although we do not presently intend to repurchase additional shares in the near term under our existing repurchase program, if we do, we expect to finance any such potential stock repurchases from existing cash and cash flows from operations.

In October 2009, we committed to invest up to $102.7 million in Celtic Therapeutics Holdings L.P. Celtic is an investment partnership organized for the purpose of identifying, acquiring and investing in a diversified portfolio of novel therapeutic product candidates, with a focus on mid-stage compounds that have progressed through human proof of concept studies that are targeted to address unmet medical needs. As of June 30, 2010, we had invested a total of $32.7 million of the aggregate commitment and had an investment balance of $27.6 million, which includes cumulative investment losses to date. We expect to invest the remainder of our commitment over a period of four years.

In 2010, we entered into a non-revolving line of credit agreement to loan Celtic Pharma Development Services Bermuda Ltd., a subsidiary of Celtic Pharmaceutical Holdings L.P., up to $18.0 million for trade payables in connection with a specified drug candidate. Celtic Pharma Development Services Bermuda Ltd. has appointed us to conduct certain clinical studies on the specified drug candidate. Principal and interest are due and payable no later than June 30, 2013 and are secured by a guarantee of an affiliate of the borrower. As of June 30, 2010, we had advanced $4.0 million to the borrower.

As of June 30, 2010, we had commitments to invest up to an aggregate additional $12.8 million in four venture capital funds and $2.1 million in other investments. For further details, see Note 3 in the notes to the consolidated condensed financial statements.

As of June 30, 2010, our total gross unrecognized tax benefits were $30.3 million and of which, $15.7 million, if recognized, would reduce our effective tax rate. We believe that it is reasonably possible that the total amount of unrecognized tax benefits could decrease by up to $4.7 million within the next twelve months due to the settlement of audits and the expiration of statutes of limitations.

Our policy for recording interest and penalties associated with tax audits is to record them as a component of provision for income taxes. For the first six months ended June 30, 2010, we recorded $0.7 million and $0.1 million, respectively, of interest and penalties as expense in our statement of income. As of June 30, 2010, we accrued $6.0 million of interest and $1.1 million of penalties with respect to uncertain tax positions. To the extent these interest and penalties are not assessed, we will reduce amounts accrued and reflect them as a reduction of the overall income tax provision.

Under most of our agreements for Development services, we typically agree to indemnify and defend the sponsor against third-party claims based on our negligence or willful misconduct. Any successful claims could have a material adverse effect on our financial statements.

We expect to continue expanding our operations through internal growth, strategic acquisitions and investments. We expect to fund these activities, the payment of future cash dividends and potential repurchases of stock, if any, from existing cash, cash flows from operations and, if necessary or appropriate, borrowings under future credit facilities. We believe that these sources of liquidity will be sufficient to fund our operations, dividends and stock repurchases, if any, for the foreseeable future. From time to time, we evaluate potential acquisitions, investments and other growth and strategic opportunities that might require additional external financing, and we might seek funds from public or private issuances of equity or debt securities. While we believe we have sufficient liquidity to fund our operations for the foreseeable future, our sources of liquidity and ability to pay dividends or repurchase our stock could be affected by current and anticipated difficult economic conditions; our dependence on a small number of industries and clients; compliance with regulations; reliance on key personnel; breach of contract, personal injury or other tort claims; international risks; environmental or intellectual property claims; or other factors described below under “Potential Liability and Insurance”, “Potential Volatility of Quarterly Operating Results and Stock Price” and “Quantitative and Qualitative Disclosures about Market Risk”. In addition, see “Risk Factors,” “Contractual Obligations” and “Critical Accounting Policies and Estimates” in our Annual Report on Form 10-K for the year ended December 31, 2009.

32

Off-Balance Sheet Arrangements

From time to time, we cause letters of credit to be issued to provide credit support for guarantees, contractual commitments and insurance policies. The fair values of the letters of credit reflect the amount of the underlying obligation and are subject to fees competitively determined in the marketplace. As of June 30, 2010, we had four letters of credit outstanding for a total of $1.8 million. We have no other off-balance sheet arrangements except for operating leases entered into during the normal course of business.

Contractual Obligations

There have been no significant changes to the Contractual Obligation table included in our Annual Report on Form 10-K for the year ended December 31, 2009.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect reported amounts and related disclosures. We have discussed those estimates that we believe are critical and require the use of complex judgment in their application in our 2009 Annual Report on Form 10-K. There were no material changes to our critical accounting policies and estimates in the first six months of 2010. For detailed information on our critical accounting policies and estimates, see our Annual Report on Form 10-K for the year ended December 31, 2009.

Recent Accounting Pronouncements

In June 2009, the Financial Accounting Standards Board, or FASB, issued a new accounting standard modifying how a company determines when an entity that is insufficiently capitalized or is not controlled through voting (or similar rights) should be consolidated. This standard clarifies that the determination of whether a company is required to consolidate an entity is based on, among other things, an entity’s purpose and design and a company’s ability to direct the activities of the entity that most significantly impact the entity’s economic performance. This standard requires an ongoing reassessment of whether a company is the primary beneficiary of a variable interest entity and requires additional disclosures about a company’s involvement in variable interest entities and any significant changes in risk exposure due to that involvement. This standard was effective January 1, 2010. The adoption of this standard had no impact on our financial statements.

In March 2010, the Emerging Issues Task Force of the FASB issued a new standard, the objective of which is to establish a revenue recognition model for contingent consideration that is payable upon the achievement of an uncertain future event, referred to as a milestone. This consensus will apply to milestones in single or multiple-deliverable arrangements involving research and development transactions, and will be effective for fiscal years (and interim periods within those fiscal years) beginning on or after June 15, 2010. We do not expect the adoption of this standard to have a material impact on our financial statements.

Income Taxes

Because we conduct operations on a global basis, our effective tax rate has and will continue to depend upon the geographic distribution of our pretax earnings among locations with varying tax rates. Our profits are also impacted by changes in the tax rates and tax laws of the various tax jurisdictions as applied to certain items of income and loss recognized for GAAP purposes. In particular, as the geographic mix of our pretax earnings among various tax jurisdictions changes, our effective tax rate might vary from period to period. The effective rate will also change due to the discrete recognition of tax benefits when tax positions are effectively settled or as a result of specific transactions.

Inflation

Our long-term contracts, those in excess of one year, generally include an inflation or cost of living adjustment for the portion of the services to be performed beyond one year from the contract date. In the event that actual inflation rates are greater than our contractual inflation rates or cost of living adjustments, inflation could have a material adverse effect on our operations or financial condition.

33

Potential Liability and Insurance

Drug development services involve the testing of potential drug candidates on human volunteers pursuant to a study protocol. This testing exposes us to the risk of liability for personal injury or death to volunteers and participants resulting from, among other things, possible unforeseen adverse side effects or improper administration of the study drug or use of the drug following regulatory approval. We attempt to manage our risk of liability for personal injury or death to volunteers and participants from administration of study products through standard operating procedures, patient informed consent, contractual indemnification provisions with clients and insurance. We monitor clinical trials in compliance with government regulations and guidelines. We have established global standard operating procedures intended to satisfy regulatory requirements in all countries in which we have operations and to serve as a tool for controlling and enhancing the quality of drug development services. The contractual indemnifications generally do not protect us against our own actions, such as gross negligence. We currently maintain professional liability insurance coverage with limits we believe are adequate and appropriate.

Potential Volatility of Quarterly Operating Results and Stock Price

Our quarterly and annual operating results have fluctuated in the past, and we expect that they will continue to fluctuate in the future. Factors that could cause these fluctuations to occur include:

• the timing and level of new business authorizations;

• the timing of the initiation, progress or cancellation of significant projects;

• our dependence on a small number of industries and clients;

• our ability to properly manage our growth or contraction in our business;

• the timing and amount of costs associated with integrating acquisitions;

• our ability to recruit and retain experienced personnel;

• the timing and extent of new government regulations;

• impairment of investments or intangible assets;

• litigation costs;

• the timing of the opening of new offices;

• the timing of other internal expansion costs;

• exchange rate fluctuations between periods;

• the mix of products and services sold in a particular period;

• pricing pressure in the market for our services;

• rapid technological change;

• the timing and amount of start-up costs incurred in connection with the introduction of new products and services; and

• intellectual property risks.

Delays and terminations of trials are often the result of actions taken by our clients or regulatory authorities, and are not typically controllable by us. Because a large percentage of our operating costs are relatively fixed while revenue is subject to fluctuation, variations in the timing and progress of large contracts can materially affect our quarterly operating results. For these reasons, we believe that comparisons of our quarterly financial results are not necessarily meaningful and should not be relied upon as an indication of future performance.

Fluctuations in quarterly results, actual or anticipated changes in our dividend policy or stock repurchase plan or other factors, including recent general economic and financial market conditions, could affect the market price of our common stock. These factors include ones beyond our control, such as changes in revenue and earnings estimates by analysts, market conditions in our industry, disclosures by product development partners and actions by regulatory authorities with respect to potential drug candidates, changes in pharmaceutical, biotechnology and medical device industries and the government sponsored clinical research sector, and general economic conditions. Any effect on our common stock could be unrelated to our longer-term operating performance. For further details, see “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2009.

34

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are exposed to foreign currency risk by virtue of our international operations. We derived 39.5% and 42.5% of our net revenue for the three months ended June 30, 2009 and 2010, respectively, from operations outside the United States. We generally reinvest funds generated by each subsidiary in the country where they are earned. Accordingly, we are exposed to adverse movements in foreign currencies, predominately in the pound sterling, euro and Brazilian real.

The vast majority of our contracts are entered into by our U.S. or U.K. subsidiaries. The contracts entered into by the U.S. subsidiaries are almost always denominated in U.S. dollars. Contracts entered into by our U.K. subsidiaries are generally denominated in U.S. dollars, pounds sterling or euros, with the majority in U.S. dollars. Although an increase in exchange rates for the pound sterling or euro relative to the U.S. dollar increases net revenue from contracts denominated in these currencies, income from operations is negatively affected due to an increase in operating expenses that occurs when we convert our expenses from local currencies into the U.S. dollar equivalent.

We also have currency risk resulting from the passage of time between the recognition of revenue, the invoicing of clients under contracts and the collection of client payments against those invoices. If a contract is denominated in a currency other than the subsidiary’s local currency, we recognize an unbilled receivable at the time of revenue recognition and a receivable at the time of invoicing for the local currency equivalent of the foreign currency invoice amount. Changes in exchange rates from the time we recognize revenue until the client pays will result in our receiving either more or less in local currency than the amount that was originally invoiced. We recognize this difference as a foreign currency transaction gain or loss, as applicable, and report it in other income, net. If the exchange rate on accounts receivable balances denominated in pounds sterling and euros had increased by 10%, our foreign currency transaction loss would have increased by $3.0 million at June 30, 2010.

Our strategy for managing foreign currency risk relies primarily on receiving payment in the same currency used to pay expenses and other non-derivative hedging strategies. From time to time, we also enter into foreign currency hedging activities in an effort to manage our potential foreign exchange exposure. If the U.S. dollar had weakened an additional 10% relative to the pound sterling, euro and Brazilian real in the second quarter of 2010, income from continuing operations, including the impact of hedging, would have been approximately $0.5 million lower for the quarter based on revenues and the costs related to our foreign operations. From time to time, we also enter into foreign currency hedging activities in an effort to manage our potential foreign exchange exposure. We have hedged a significant portion of our foreign currency exposure for the remainder of 2010.

Changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of foreign subsidiaries’ financial results into U.S. dollars for purposes of reporting our consolidated condensed financial results. The process by which we translate each foreign subsidiary’s financial results to U.S. dollars is as follows:

• we translate statement of income accounts at average exchange rates for the period;

• we translate balance sheet assets and liability accounts at end of period exchange rates; and

• we translate equity accounts at historical exchange rates.

Translation of the balance sheet in this manner affects shareholders’ equity through the cumulative translation adjustment account. This account exists only in the foreign subsidiary’s U.S. dollar balance sheet and is necessary to keep the foreign balance sheet, stated in U.S. dollars, in balance. We report translation adjustments with accumulated other comprehensive income (loss) as a separate component of shareholders’ equity. To date, cumulative translation adjustments have not been material to our consolidated condensed financial position. However, future translation adjustments could materially and adversely affect us.

Currently, there are no material exchange controls on the payment of dividends or otherwise prohibiting the transfer of funds out of any country in which we conduct operations. Although we perform services for clients located in a number of jurisdictions, we have not experienced any material difficulties in receiving funds remitted from foreign countries. However, new or modified exchange control restrictions could have an adverse effect on our financial condition. If we were to repatriate dividends from the cumulative amount of undistributed earnings in foreign entities, we would incur a tax liability which is not currently provided for in our consolidated condensed balance sheet.

35

We are exposed to changes in interest rates on our cash, cash equivalents and investments and amounts outstanding under notes payable and lines of credit. We invest our cash and investments in financial instruments with interest rates based on market conditions. If the interest rates on cash, cash equivalents and investments decreased by 10%, our interest income would have decreased by approximately $0.1 million in the second quarter of 2010.

We are also exposed to market risk related to our investments in auction rate securities. For further details, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources”.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) are designed only to provide reasonable assurance that information to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15(b). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report to provide the reasonable assurance discussed above.

Internal Control Over Financial Reporting

No change to our internal control over financial reporting occurred during the second quarter of 2010 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Part II. OTHER INFORMATION

Item 6. Exhibits

(a) Exhibits

10.162	Form of Severance Agreement, originally dated January 1, 2001, between Pharmaceutical Product Development, Inc. and various individuals.
31.1	Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)
31.2	Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)
32.1	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of The Sarbanes-Oxley Act of 2002 – Chief Executive Officer
32.2	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of The Sarbanes-Oxley Act of 2002 – Chief Financial Officer

36

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
	(Registrant)
By	/s/ David L. Grange
	Chief Executive Officer
	(Principal Executive Officer)
By	/s/ Daniel G. Darazsdi
	Chief Financial Officer
	(Principal Financial Officer)
By	/s/ Peter Wilkinson
	Chief Accounting Officer
	(Principal Accounting Officer)

Date: August 6, 2010

37

EX-10.162

Exhibit 10.162

Employee	Section 2.01 Base Salary and Bonus Multiplier	Section 2.03 Welfare Benefit Period
Fredric N. Eshelman	3.0	2 years
David L. Grange	3.0	2 years
William Sharbaugh	2.0	2 years
Daniel G. Darazsdi	2.0	2 years
Christine A. Dingivan	2.0	2 years
Brainard Judd Hartman	2.0	2 years
Michael O. Wilkinson	1.0	1 year
Edward J. Murray	1.0	1 year
Paul D. Colvin	1.0	1 year
Lee E. Babiss	1.0	1 year
Henrietta N. Ukwu	1.0	1 year

SEVERANCE AGREEMENT

THIS AGREEMENT, effective the 1st day of January, 2001, by and between Pharmaceutical Product Development, Inc. and its subsidiaries and affiliates (collectively, “PPD”) and                      (“Employee”).

WHEREAS, Employee is a valued employee of PPD and in order to induce Employee to remain in the employ of PPD, PPD desires to provide the severance benefits hereinafter described in the event of a “Change in Control”, as hereinafter defined, of PPD.

NOW, THEREFORE, it is agreed as follows:

1. Definitions

1.01 “AFR” means the interest rate determined under Section 1274 of the Code.

1.02 “Base Amount” shall have the meaning set forth and shall be determined as provided in Section 280G of the Code.

1.03 “Change in Control” means (i) a change of control of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A promulgated under the Securities Exchange Act of 1934, as amended (“Exchange Act”), provided that such a Change in Control shall be deemed to have occurred if any “person” (as such term is used in Sections 13(d) and 14(d)(2) of the Exchange Act) is or becomes the beneficial owner, directly or indirectly, of securities of PPD representing 50% or more of the combined voting power of PPD’s then outstanding securities; (ii) a sale of substantially all of the assets of PPD; or (iii) a liquidation of PPD.

1.04 “Constructive Termination” means a termination of Employee’s employment by PPD during the Covered Period initiated by Employee after (i) a substantial diminution or alteration in the duties of Employee, (ii) a reduction by PPD in Employee’s base salary in effect on the date of the Change in Control, or (iii) the relocation of Employee’s primary work location to a location that is more than twenty-five (25) miles from Employee’s primary work location prior to the Change in Control. Constructive Termination specifically does not include termination of Employee by reason of death, Disability or retirement at or after age 65. Employee shall give PPD written notice of a Constructive Termination, which notice shall provide a brief description of the circumstances which Employee asserts gives rise to a right of Constructive Termination, and PPD shall have ten (10) days from receipt of said notice within which to remedy said circumstances.

1.05 “Covered Payment” means the amounts and benefits paid to Employee pursuant to this Agreement, taken together with any amounts or benefits otherwise paid or distributed to Employee by PPD.

1.06 “Covered Period” means the time period commencing on the date of and coincident with a Change of Control and ending one year thereafter.

1.07 “Disability” means the inability of Employee to perform his assigned duties for PPD for a period of three (3) months due to Employee’s physical or mental illness as determined by a reputable medical doctor.

1.08 “Excess Parachute Payment” shall have the meaning set forth and shall be determined as provided in Section 280G of the Code.

1.09 “Excise Tax” shall mean the tax imposed under Section 4999 of the Code on an Excess Parachute Payment.

1.10 “Executive Consultant” shall mean the executive compensation or comparable consultant used from time to time by PPD in designing its compensation program for executive and senior management employees of PPD; provided, however, that in its sole discretion PPD may at any time designate its independent auditors as its Executive Consultant for the purpose of performing any calculations required under Section 2.05 of this Agreement.

1.11 “Final Determination” means a final determination by a court of competent jurisdiction or a proceeding of the Internal Revenue Service or its successor agency.

1.12 “First Period” means the twelve-month period ending on the Termination Date.

1.13 “Internal Revenue Code” means the Internal Revenue Code of 1986 as heretofore or hereafter amended, and any successor code. References in this agreement to specific sections of the Code shall also include any successor sections.

1.14 “Parachute Payments” shall have the meaning set forth and shall be determined as provided in Section 280G of the Code.

1.15 “Payment Cap” means the maximum amount which may be paid to Employee under the terms of this Agreement without subjecting Employee to the Excise Tax.

1.16 “Payment Date” means the date thirty (30) days following the Termination Date.

1.17 “Stock Awards” means Employee’s outstanding awards of PPD non-qualified stock options or restricted stock as of the Termination Date.

1.18 “Termination for Cause” means (i) an act or acts involving fraud, embezzlement or theft from PPD, (ii) Employee’s willful and repeated failure to follow directions of the Board of Directors that continues for at least ten (10) days following written notice of the Board of Directors of such failure to follow directions, or (iii) termination for cause as defined in and made pursuant to a then effective employment agreement, if any, between Employee and PPD.

1.19 “Termination Date” means the date on which Employee’s employment is terminated such that Employee is entitled to the compensation and benefits provided for in Section 2 of this Agreement.

2. Compensation Upon Change of Control. If during the Covered Period (i) PPD terminates Employee’s employment for reason other than Termination for Cause or (ii) Employee’s employment is terminated by reason of Constructive Termination, Employee shall be entitled to the following compensation and benefits:

2.01 Base Salary and Bonus. PPD shall pay Employee an amount equal to              times the sum of Employee’s (i) base salary for the First Period (determined as if Employee was employed for the entire First Period if employed for less than the First Period) and (ii) the greater of (x) Employee’s target bonus under the PPD incentive cash bonus plan in which Employee is eligible to participate immediately prior to the Termination Date or (y) the average of the cash bonuses received in the First Period and in the twelve-month period immediately preceding the First Period, said amount to be paid on the Payment Date.

2.02 Unpaid and Deferred Compensation. PPD shall pay Employee any bonus or deferred compensation (whether in the form of cash, stock or otherwise) accrued but unpaid as of the Termination Date, said sum to be paid on the Payment Date.

2.03 Benefits. For a period of                      after the Termination Date, PPD shall continue to pay for and provide welfare benefits which Employee was receiving immediately prior to the Termination Date, including life insurance, health, medical, dental, vision and wellness, accidental death and dismemberment and disability benefits; provided, however, that PPD’s obligations under this clause shall terminate from the date that Employee first becomes eligible after the Termination Date for similar coverage under another employer’s plan.

2.04 Stock Awards. Notwithstanding anything to the contrary in any agreement for Stock Awards, (i) all unvested shares underlying Stock Awards granted more than six months prior to the Termination Date shall become fully vested as of the Termination Date, and (ii) Employee shall continue to be treated under each award agreement evidencing a Stock Award as if Employee was an employee of PPD until the first to occur of (x) the third anniversary of the Termination Date, or (y) the expiration of

the exercise period provided for therein; provided, however, in the event of Employee’s death or his disability (as disability is defined in the award agreement) after the Termination Date, the time for exercise after death or such disability prescribed in the award agreement shall apply. The provisions of this Section 2.04 shall also apply to any and all substitute awards for nonqualified stock options and restricted stock granted to Employee in exchange for Stock Awards to which this section applies.

2.05 Limitation on Payments.

a. Application of Section 2.05. If a Covered Payment hereunder would be an Excess Parachute Payment and would thereby subject Employee to the Excise Tax, the provisions of this Section 2.05 shall apply to determine the amounts payable to Employee pursuant to this Agreement.

b. Calculation of Benefits. At least fifteen (15) days prior to the Payment Date, PPD shall notify Employee of the aggregate present value of all amounts and benefits to which Employee would be entitled under this Agreement and any other plan, program or arrangement with PPD as of the Termination Date, together with the projected maximum payments, determined as of such Date of Termination, that could be paid without Employee being subject to the Excise Tax.

c. Imposition of Payment Cap. If (i) the aggregate value of all amounts and benefits to which Employee would be entitled under this Agreement and any other plan, program or arrangement with PPD exceeds the amount which can be paid to Employee without Employee incurring an Excise Tax and (ii) Employee would receive a greater net after-tax amount (taking into account all applicable taxes payable by Employee, including an Excise Tax) by applying the limitation contained in this Section 2.05(c), then the amounts otherwise payable to Employee under this Section 2 shall be reduced to an amount equal to the Payment Cap. If Employee receives reduced payments and benefits hereunder, Employee shall have the right to designate which of the payments and benefits otherwise provided for in this Agreement that Employee will receive in connection with the application of the Payment Cap.

d. Application of Code Section 280G. The Executive Consultant shall determine whether any part of the Covered Payment will be subject to the Excise Tax and the amount of such Excise Tax. For purposes of such determination, the Executive Consultant shall take into consideration and be guided by the following:

(i) such Covered Payment will be treated as Parachute Payments and all Parachute Payments in excess of the Base Amount shall be treated as subject to the Excise Tax, unless and except to the extent that in the good faith judgment of the Executive Consultant, PPD has a reasonable basis to conclude that such Covered Payment, in whole or in part, either do not constitute Parachute Payments or represent reasonable compensation for personal services actually rendered (within the meaning of Section 280G of the Code) in excess of the Base Amount, or such Parachute Payments are otherwise not subject to the Excise Tax, and

(ii) the value of any noncash benefits or any deferred payment or benefit shall be determined by the Executive Consultant in accordance with the principles of Section 280G of the Code.

(e) Applicable Tax Rates. For purposes of determining whether Employee would receive a greater net after-tax benefit if the amounts payable under this Agreement are reduced in accordance with Section 2.05(c), Employee shall be deemed to pay:

(i) federal income taxes at the highest applicable marginal rate of federal income taxation for the calendar year in which the first amounts are to be paid hereunder, and

(ii) any applicable state and local income taxes at the highest applicable marginal rate of taxation for such calendar year, net of the maximum reduction in federal income taxes which could be obtained from the deduction of such state or local taxes if paid in such year;

provided, however, that Employee may request that such determination be made based on Employee’s individual tax circumstances, which shall govern such determination so long as Employee provides to the Executive Consultant such information and documents as the Executive Consultant shall reasonably request to determine such individual circumstances.

(f) Adjustments in Respect to Payment Cap.

(i) If Employee receives reduced payments and benefits under Section 2.05 or if Section 2.05 is determined not to be applicable to Employee because the Executive Consultant concludes that Employee is not subject to any Excise Tax, and it is established pursuant to a Final Determination that, notwithstanding the good faith of Employee and PPD in applying the terms of this Agreement, the aggregate Parachute Payments paid to Employee or for Employee’s benefit are in an amount that would result in Employee being subject to an Excise Tax and Employee would still be subject to the Payment Cap under the provisions of Section 2.05(c), then the amount in excess of the Payment Cap shall be deemed for all purposes to be a loan to Employee made on the date of the receipt of such excess payment, which Employee shall have an obligation to repay to PPD on demand, together with interest at the AFR, from the date of the payment hereunder to the date of repayment by Employee.

(ii) If Section 2.05 is not applied to reduce Employee’s entitlements under this Section 2 because the Executive Consultant determines that Employee would not receive a greater net after-tax benefit by applying Section 2.05 and it is established pursuant to a Final Determination that, notwithstanding the good faith of Employee and PPD in applying the terms of this Agreement, Employee would have received a greater net after-tax benefit by subjecting Employee’s payments and benefits

hereunder to the Payment Cap, then the aggregate Parachute Payments paid to Employee or for Employee’s benefit in excess of the Payment Cap shall be deemed for all purposes a loan to Employee made on the date of receipt of such excess payments, which Employee shall have an obligation to repay to PPD on demand, together with interest at the AFR, from the date of payment hereunder to the date of repayment by Employee.

(iii) If Employee receives reduced payments and benefits by reason of this Section 2.05 and it is established pursuant to a Final Determination that Employee could have received a greater amount without exceeding the Payment Cap, then PPD shall promptly thereafter pay Employee the aggregate additional amount which could have been paid without exceeding the Payment Cap, together with interest on such amount at the AFR, from the original payment due date to the date of actual payment by PPD.

3. Miscellaneous.

3.01 Successor-in-Interest. PPD will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of PPD, to expressly assume and agree to perform this Agreement in the same manner and to the same extent that PPD would be required to perform it if no succession had taken place.

3.02 Binding Effect. This Agreement shall inure to the benefit of and be enforceable by Employee’s personal or legal representatives, executives, administrators, successors, heirs, distributees, devisees and legatees.

3.03 Notice. For purposes of this Agreement, notices and all other communications provided for in the Agreement shall be in writing and shall be given (i) by certified mail, return receipt requested, postage prepaid, (ii) by personal delivery or (iii) by recognized overnight carrier, and shall be deemed received when actually received. Notices shall be addressed as follows:

If to PPD:	Pharmaceutical Product Development, Inc.
	929 North Front Street
	Wilmington, North Carolina 28401
	Attention: Chief Executive Officer
If to Employee:

Either party hereto may change the notice address by giving notice thereof in the manner provided for herein.

3.04 Waiver. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any provision or condition of this Agreement to be performed by such other party shall be deemed a subsequent waiver of the same or similar provisions or conditions.

3.05 Entire Agreement. No agreements or representations, oral or otherwise, expressed or implied, with respect to the subject matter hereof have been made by either party which are not set forth expressly in this agreement, and this Agreement supersedes and replaces in its entirety all prior agreements and representations, expressed, implied, oral or otherwise, made by PPD to or with Employee, including but not limited to that certain Severance Agreement dated                      between PPD and Employee.

3.06 Governing Law. This Agreement shall be governed by and interpreted under the laws of the State of North Carolina.

3.07 Unenforceability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement.

3.08 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

3.09 Headings. Headings used in this Agreement are for convenience only and shall not be used to construe or interpret this Agreement.

3.10 Enforcement by Employee. All legal expenses incurred by Employee in the successful enforcement of any of the terms of this Agreement shall be paid by PPD.

IN WITNESS WHEREOF, the parties have executed this Agreement effective the date first hereinabove set forth.

Pharmaceutical Product Development, Inc.	Employee
By:
Name:	Name:
Title:

EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, David L. Grange, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Pharmaceutical Product Development, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 6, 2010	By:	/s/ David L. Grange
		Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATION

I, Daniel G. Darazsdi, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Pharmaceutical Product Development, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 6, 2010	By:	/s/ Daniel G. Darazsdi
		Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Pharmaceutical Product Development, Inc. (“PPD”) on Form 10-Q for the period ended June 30, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David L. Grange, Chief Executive Officer of PPD, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of PPD as of, and for, the periods presented in the Report.

Date: August 6, 2010

/s/ David L. Grange

David L. Grange

Chief Executive Officer

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Pharmaceutical Product Development, Inc. (“PPD”) on Form 10-Q for the period ended June 30, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Daniel G. Darazsdi, Chief Financial Officer of PPD, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of PPD as of, and for, the periods presented in the Report.

Date: August 6, 2010

/s/ Daniel G. Darazsdi

Daniel G. Darazsdi

Chief Financial Officer